

European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause

Mary Ann Lumsden,^{1,*} Olaf M. Dekkers,^{2,3,4} Stephanie S. Faubion,⁵
Angelica Lindén Hirschberg,^{6,7} Channa N. Jayasena,⁸ Irene Lambrinoudaki,⁹
Yvonne Louwers,¹⁰ JoAnn V. Pinkerton,¹¹ Antoan Stefan Sojat,¹² and Leonie van Hulsteijn^{2,13}

¹Hon Professor of Medical Education and Gynaecology, University of Glasgow, Glasgow G12 8QQ, United Kingdom

²Department of Clinical Epidemiology, Leiden University Medical Center, 2333 ZG Leiden, The Netherlands

³Department of Endocrinology and Metabolism, Leiden University Medical Center, 2333 ZG Leiden, The Netherlands

⁴Department of Clinical Epidemiology, Aarhus University, 8000 Aarhus, Denmark

⁵Department of Medicine, Mayo Clinic, Jacksonville, Florida and Mayo Clinic Center for Women's Health, Rochester, MN 55901, United States

⁶Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden

⁷Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden

⁸Department of Metabolism, Digestion & Reproduction, Imperial College London, London SW7 2AZ, United Kingdom

⁹Menopause Unit, 2nd Department of Obstetrics and Gynecology, School of Medicine, National and Kapodistrian University of Athens, Aretaieon University Hospital, Athens 115 28, Greece

¹⁰Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands

¹¹Professor of Obstetrics and Gynecology, Division Director Midlife Health, The University of Virginia Health System Charlottesville, Charlottesville, VA 22908, United States

¹²National Centre for Infertility and Endocrinology of Gender, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Centre of Serbia, Serbia

¹³European Society of Endocrinology, Bristol BS32 4QW, United Kingdom

*Corresponding author: Hon Professor of Medical Education and Gynaecology, University of Glasgow, University Avenue, G12 8QQ Glasgow, United Kingdom. Email: maryann.lumsden@glasgow.ac.uk

Abstract

Women make up 51% of the world's population, and the global population of postmenopausal women is growing. About 25% of these women experience debilitating menopausal symptoms. Since it is important that all health care professionals have a fundamental knowledge of managing women presenting with symptoms related to the menopause, this European Society of Endocrinology Clinical Practice Guideline was developed. It provides guidance on evaluation and optimal clinical management of women who go through the menopause in middle age, those with Premature Ovarian Insufficiency (POI), Early Menopause and those for whom hormones are not appropriate, including women with, or at high risk of, breast cancer. This guideline discusses the benefits and risks of hormone therapy administration as well as summarizing other treatments for menopausal symptoms. Further, the contentious issue of the impact of menopausal hormone therapy in the prevention of chronic disease is considered.

Keywords: menopause, perimenopause, premature ovarian insufficiency, menopausal hormone therapy, hormone replacement therapy

Summary of recommendations

Evaluation

R 1.1 We recommend that menopause is considered as a spectrum and includes the perimenopause and postmenopause. (Good Clinical Practice)

R 1.2 We recommend that perimenopause is considered when menstrual irregularity and/or vasomotor symptoms (VMS) are present, even in younger women (40–45 years). (Good Clinical Practice)

R 1.3 We recommend that premature ovarian insufficiency (POI) is considered in women under 40 years of age in the presence of menstrual irregularity and/or subfertility and/or vasomotor symptoms. (Good Clinical Practice)

R 1.4 We recommend biochemical testing for diagnosis or management of (peri)menopause in women older than 45 years is not necessary. (Good Clinical Practice)

R 1.5 We recommend biochemical testing for the presence of POI in women under 40 years of age in the presence of menstrual irregularity and/or subfertility and/or vasomotor symptoms; biochemical testing for the presence of perimenopause or menopause can also be considered in women aged 40–45 years. (Good Clinical Practice)

R 1.6 If biochemical testing for perimenopause is considered, we suggest measuring FSH at day 2 to 5 of the menstrual cycle or after an interval greater than 40 days without menstruation. (Good Clinical Practice)

R 1.7 We recommend that, when the medical history and clinical presentation of a woman of reproductive age include

interference with the menstrual cycle and/or lead to menopause-like symptoms, other diagnoses should be considered. These may require additional testing. (Good Clinical Practice)

R 1.8 We recommend that all women with POI are referred to a menopause expert and where possible, a multidisciplinary team. (Good Clinical Practice)

R 1.9 We suggest that where possible, women in perimenopause, who are under the age of 40 and have apparent contraindications for hormone replacement therapy, are referred to a unit with particular expertise in managing such women. These include, for example, women with a history or high risk of a hormone dependent cancer, thrombotic or cardiovascular high risk, women who have an inadequate response to hormone therapy or those who have significant adverse effects.

Management

R 2.1 We recommend that a holistic approach is taken for women during perimenopause and menopause, not having a sole focus on hormone replacement therapy (HRT)/ menopausal hormone therapy (MHT). (Good Clinical Practice)

R 2.2 We recommend that women in peri- and postmenopause who are appropriate candidates for MHT can be managed in primary care according to recognized guidelines.

R 2.3 We recommend that before starting HRT/MHT women are well-informed about the benefits and risks of treatment and other options in order to facilitate shared decision making. (Good Clinical Practice)

R 2.4 We recommend, if indicated, in women with a uterus, to start MHT with a preparation combining oestrogen and progestogen. (⊕⊕⊕⊕)

R 2.5 We recommend, if indicated, in women without a uterus, to start MHT with a preparation with oestrogen alone. (⊕⊕⊕⊕)

R 2.6 We recommend that in women treated with MHT for symptoms, treatment effects should be re-evaluated after 3 months. In case of an inadequate response, adverse effects or intolerability, dose and formulation should be re-evaluated. (Good Clinical Practice)

R 2.7 We recommend taking into account individual characteristics and comorbidities when prescribing MHT and also, preference, availability and costs when choosing between transdermal and oral preparations. (Good Clinical Practice)

R 2.8 We recommend HRT in POI irrespective of the presence of vasomotor—or other climacteric symptoms as the multimodal benefits clearly exceed the risk. HRT should be continued until the anticipated age of natural menopause and then the ongoing prescription reevaluated periodically. (Good Clinical Practice)

R 2.9 We recommend initiating MHT in women within 10 years of natural menopause onset or under 60 years for bothersome menopausal symptoms such as vasomotor or other climacteric symptoms. (⊕⊕⊕⊕⊕) Women should also be informed that MHT prevents bone loss and reduces fracture risk and may have positive effects on the cardiovascular system. (Good Clinical Practice)

R 2.10 We suggest that for women with symptoms of vulvovaginal atrophy local or systemic MHT can be considered depending on the presence of other symptoms. Local oestrogen is usually started alone but can be administered with systemic MHT if needed. (⊕⊕⊕⊕)

R 2.11 We suggest that in women without symptoms of perimenopause/menopause who are under 60 years of age, MHT initiation might be considered for bone protection. (⊕⊕⊕⊕)

Specific conditions

Age

R 3.1 We suggest a targeted approach to MHT continuation in women over 60 yrs. We suggest taking into account the effect on VMS and/or other climacteric symptoms, the changing benefit-risk profile with age and effect on bone and personal preferences. (Good Clinical Practice)

Venous thromboembolism (VTE)

R 3.2 We recommend that, if in a woman with a previous VTE, HRT/MHT is indicated after individual risk—benefit assessment, transdermal low dose oestrogen should be used. (⊕⊕⊕⊕)

Cardiovascular disease

R 3.3 MHT should not be used primarily for primary or secondary prevention of cardiovascular disease (CVD). (⊕⊕⊕⊕)

Diabetes

R 3.4 We recommend that well-controlled diabetes is not considered a contraindication for MHT use; transdermal oestrogen is the preferred choice. (⊕⊕⊕⊕)

Hypertension

R 3.5 In women with well-controlled hypertension there is no contra-indication for MHT; transdermal oestrogen is the preferred choice. (⊕⊕⊕⊕) We recommend MHT not be initiated in the presence of uncontrolled hypertension. (Good Clinical Practice)

Stroke

R 3.6 We recommend that MHT is not used to prevent stroke. (⊕⊕⊕⊕)

Migraine

R 3.7 We suggest that in women with an indication for MHT and a history of migraine with aura, transdermal oestrogen is recommended. (⊕⊕⊕⊕)

Breast cancer

R 3.8 We recommend that all women initiating MHT are informed about the increased risk for breast cancer. (Good Clinical Practice)

R 3.9 We recommend that systemic MHT is not used in women with a history of breast cancer. Considerations include factors such as age and individual characteristics of the tumour. (⊕⊕⊕⊕)

R 3.10 We suggest that low dose vaginal oestrogen, dosed to treat vaginal issues, can be considered in women with a history of breast cancer and genitourinary symptoms if other non-hormonal therapies are ineffective. (⊕⊕⊕⊕)

Endometrial cancer

R 3.11 We suggest that initiation of MHT can be considered in women with a history of early stage endometrial cancer who are considered disease free. (⊕○○○)

Ovarian cancer

R 3.12 We suggest that the risk for ovarian cancer is not a major determinant for the decision to initiate MHT or not. (⊕○○○)

R 3.13 We suggest that initiation of MHT can be considered in women with (a history of) certain subtypes of ovarian cancer. (⊕○○○)

Mood and cognition

R 3.14 We recommend not to routinely use MHT to treat clinical depression in perimenopause/menopause. (⊕○○○)

Dementia

R 3.15 We recommend that MHT is not used to prevent or treat dementia (⊕○○○)

Introduction

Women who have functioning ovaries at some point during their reproductive years will go through menopause if they live long enough, and therefore menopause can be considered a normal component of aging. A proportion of those women will experience symptoms that impair quality of life and will seek treatment. It is important that all health care professionals have a fundamental knowledge of managing women presenting with symptoms related to the menopause. Menopause Hormone Therapy (MHT—often termed Hormone Replacement Therapy), is considered an appropriate option to treat these symptoms in most women.

The European Society of Endocrinology initiated this clinical practice guideline on evaluation and management of Menopause and the Perimenopause. It not only covers women who go through the menopause in middle age, but also those with Premature Ovarian Insufficiency (POI), Early Menopause and those for whom hormones are not appropriate, including women with, or at high risk of, breast cancer. It covers the diagnosis and optimal clinical management of menopause-related symptoms, including hormonal and non-hormonal therapies. This guideline discusses the benefits and risks of hormone therapy administration as well as summarizing other treatments for menopausal symptoms. The contentious issue of the impact of MHT in the prevention of chronic disease is considered.

The epidemiology of menopause

Women make up 51% of the world's population. In 2021, 26% of women globally were postmenopausal according to the WHO, and the global population of postmenopausal women is growing (Menopause). The British Menopause Society suggests that 25% of these women experience debilitating menopausal symptoms (17-BMS-TfC-What-is-the-menopause-AUGUST2023-A.pdf) and consequently the numbers being seen within many clinical specialties will increase.

Pathophysiology of menopause

Menopause is a biological stage in a woman's life marked by the cessation of menstruation and loss of fertility. A woman is defined as postmenopausal from 1 year after her last period.

The changes associated with the perimenopause (the years leading up to the menopause and 1 year after it; see [Figure 1](#)) and the menopause occur when ovarian function diminishes. This includes the cessation of both egg (oocyte) maturation and sex hormone (principally oestrogen, progesterone and anti-Müllerian hormone (AMH) secretion. Women have a finite number of oocytes at birth and the quantity declines with advancing age. The menopause is characterised by the eventual depletion of the oocyte store and cessation of menstruation. Menstrual cycle irregularity often occurs before periods stop completely.

Most tissues contain oestrogen receptors through which the hormone exerts its effects. The most immediate changes resulting from reduced oestrogen levels are evident in the regulation of the menstrual cycle. However, oestrogen depletion associated with the menopause has many other effects on the body—for example causing vasomotor, musculoskeletal, urogenital, and psychological symptoms. Oestrogen has also been shown to have an impact on the function of other systems in later life, including bones and the cardiovascular system. Oestrogen depletion explains some of the differences in the incidence of osteoporosis between men and women.

Definitions

Natural menopause is defined as the absence of menses for longer than 1 year. In Europe, it occurs at about the age of 51 years. The detailed stages of the perimenopause are described best using the STRAW criteria (see [Figure 1](#)). Menopause may occur suddenly with abrupt cessation of menses or may be a more gradual phenomenon. It is associated with elevated follicle stimulating hormone (FSH).

Early menopause is defined as menopause occurring between the age of 40 and less than 45 years.

Perimenopause is a transition phase when ovarian function declines and concentrations of oestrogen fall. It is often associated with the onset of symptoms and may last for 2-4 years. It ends 1 year after the menopause. The term is often used interchangeably with Menopause Transition (see [Figure 1](#)) although the precise definition of this can vary as it does not include one year post menopause in the STRAW criteria.

Premature Ovarian Insufficiency (POI) is the onset of menopause under the age of 40 years with amenorrhoea or irregular menstrual cycle for 4-6 months, in combination with low oestradiol and elevated gonadotrophins.

Menopausal Hormone Therapy (MHT) is hormone therapy given to women around the age of the natural menopause to treat symptoms of menopause. Both unopposed and opposed oestrogen are used depending on absence or presence of a uterus. It may be started prior to the menopause and be continued for many years after it.

Hormone Replacement Therapy (HRT) (also known as Hormone Therapy) is hormone replacement given to young women with POI or those with early menopause who have become menopausal. In this circumstance, the term “replacement” is accurate in that the aim is not only symptom management but also restoring oestrogen levels to those experienced by a premenopausal woman in order to counteract any medical complications related to oestrogen deficiency.

Symptoms of the menopause

Many women experience a range of symptoms during the menopause and perimenopause and these symptoms often




Figure 1. Stages of the menopause. Adapted in Ambikairajah A *et al.*¹ and Soules *et al.*² Within the STRAW criteria, menopause is central to the staging system and is labelled as point zero (0). There are five stages preceding the Final Menstrual Period (FMP) (–5 to –1) and two following it (+1 to +2). Stages –5 to –3 encompassed the Reproductive Interval; –2 to –1 reflect the Menopausal Transition; and +1 to +2, defined Post-menopause.² The menopausal transition (–2 to –1) begins with a variation in menstrual cycle length and rise in follicle stimulating hormone (FSH). It ends with the FMP. Early post-menopause (+1) is defined as within 5 years since the FMP and is further subdivided into segments “a”; the first 12 months after the FMP and “b”; the following 4 years. Whereas late post-menopause (+2), is defined as having a variable duration since it ended with a woman’s death. Finally, the STRAW criteria defined perimenopause (–2 to +1a) as ending 12 months after the FMP.

lessen or disappear over time. The most common include vasomotor symptoms (VMS; for example, hot flushes and sweats), effects on mood (for example, low mood) and urogenital symptoms (for example, vaginal dryness). VMS are common, occur in most ethnic groups and are influenced by ethnicity and other demographic factors.³ On average, African-American women had more hot flushes than white women, and Asian women had the fewest hot flushes. VMS may continue for 7 years or more.⁴ The same study reported that early menopause (between 40 and less than 45 years) affected 3.7% of African-American women, 2.9% of white women, 2.2% of Chinese women and 0.8% of Japanese women.

Other symptoms are sleep problems, depressed mood, anxiety and palpitations, muscle and joint discomfort and headaches and migraines.⁵ Sleep problems may be secondary to VMS occurring at night, but disturbed sleep can occur independently of hot flashes.⁶ Disturbed sleep can in turn cause fatigue, irritability and difficulties with memory and concentration. Although some of these symptoms may not be linked directly to oestrogen deficiency, they may still be alleviated by MHT. Variations in consultation patterns for menopausal symptoms depend on many factors, including cultural, ethnic, educational and psychosocial factors, as well as the impact of the symptoms on the women. However, many women want more support for managing menopausal symptoms from their health care professionals.

Clinical consequences

Postmenopausal women are at increased risk of a number of conditions, such as osteoporosis, cardiovascular disease (CVD) and changes in the vagina and bladder which occur as a result of aging, although oestrogen depletion may play a negative role.

During the latter part of the last century, menopausal hormone therapy (MHT, also known as hormone therapy (HT)

and hormone replacement therapy (HRT), see **Definitions**) was advocated for both symptom relief and chronic disease prevention. This followed publications of several observational studies suggesting a decrease in the incidence of CVD, osteoporosis and dementia, among other conditions of age. However, two influential studies—the Women’s Health Initiative (WHI)⁷ and the Million Women Study (MWS)⁸—reported on the risks and benefits associated with the use of MHT. The publication of these studies was associated with a significant reduction in women’s use of MHT/HRT throughout Europe. WHI was the biggest and only RCT of MHT/HRT and placebo and MWS was a large observational study including a wide range of participants. The earlier studies were likely affected by a healthy user bias and therefore, their results suggesting a significant decrease in CVD are less valid.

Socioeconomic status is linked to the use of MHT, with women of lower socioeconomic status being less likely to use MHT. Inequalities in referral rates have also been associated with geography and age. There is also evidence that physician speciality is associated with probability of MHT prescriptions. In the USA and in Sweden, women receiving care from gynaecologists are significantly more likely to use MHT than women receiving care from family physicians.^{9,10} Therefore, there is a need for education of all healthcare professionals.

Importantly, lifestyle is a major factor influencing the occurrence of menopausal symptoms, their severity and their treatment, for example, obesity impacts both menopausal symptoms and general health.

Methods

Guideline working group

This clinical guideline was initiated and developed on behalf of The European Society of Endocrinology (ESE). The clinical chair of the working group, Prof Mary Ann Lumsden, was

appointed by the ESE Clinical Committee. Prof Olaf Dekkers and Dr Leonie van Hulsteijn served as the methodological team and Dr Antoan Stefan Sojat as ESE Young Endocrinologists and Scientists representative. The other members were suggested by the chairs and approved by the ESE Clinical Committee, including Prof Stephanie Faubion, Prof Angelica Lindén Hirschberg, Dr Channa Jayasena, Prof Irene Lambrinoudaki, Dr Yvonne Louwers, and Prof JoAnn Pinkerton. Prior to the process, all participants completed conflict of interest forms (see [Appendix 1](#)). The process was approved by the ESE Executive Committee. There were several virtual working group meetings and one in-person meeting (Leiden, The Netherlands December 13 & 14, 2023). In between meetings the working group communicated by email.

Target groups

This guideline was developed for health care professionals who see women in (peri)menopause and beyond and who seek guidance for evaluation and management of these women. The guideline served as a source document for the preparation of patient education material published on the ESE website, to empower women and their treating clinicians.

Aims

The overall purpose of this guideline is to provide clinicians with practical guidance on the evaluation and management of women in menopause and beyond, including hormonal, non-hormonal, lifestyle, and psychosocial interventions, with an emphasis on patient-centred care. Gender-affirming hormonal therapy is not included within this guideline because the therapeutic goals and risks of therapy in transwomen are distinct to those of MHT for menopause.

In clinical practice, both the recommendations and the clinical judgment of treating clinicians should be considered. Recommendations may need adaptation to local or national circumstances.

Summary of methods used for guideline development

The methods used for establishing the guideline have been described in detail previously.^{11,12} Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) was used as a methodological basis. Clinical questions were defined (see below), followed by systematic literature searches. An average effect for specific outcomes was estimated where possible.

The recommendations took into account the quality of the evidence, the balance of desirable and undesirable outcomes, and individual values and preferences (patient preferences, goals for health, costs, management inconvenience, feasibility of implementation).^{11,13} The recommendations are worded as “*recommend*” (strong recommendation) or “*suggest*” (weak recommendation). The meaning of a strong recommendation is that all reasonably informed persons (clinicians, policy makers and patients) would want the management in accordance with the recommendation, while for a weak recommendation, most persons would still act in accordance with the guideline, but some would not.¹⁴ Formal evidence synthesis was performed and graded for recommendations addressing our initial clinical questions (see “**Clinical questions, eligibility criteria, and definition of endpoints**” section).

The quality of the evidence behind the recommendations was rated as very low (⊕○○○), low (⊕⊕○○), moderate (⊕⊕⊕○), or high (⊕⊕⊕⊕). Recommendations that were based on good clinical practice and experience of the working group members were not formally graded,¹⁵ but acknowledged in the guideline as “good clinical practice”. Recommendations that were neither based on evidence or good clinical practice, were not graded at all. Consensus was reached upon discussion; minority positions were considered in the rationale behind the recommendations.

Review process

A draft of the guideline was reviewed by patient representative Rachel Weiss (Founder of the Menopause Café charity) and four experts in the field (see **Acknowledgments** section) and was distributed to all ESE members for commenting. All comments and suggestions were then discussed and implemented as thought appropriate by the guideline working group (see [Appendix 2](#)).

Endorsement by other societies

To achieve wide acceptance of the guidelines within the clinical community of the different disciplines involved in the management of women in (peri)menopause, the draft of the guideline document was submitted to several other professional/learned societies. Finally, the following societies endorsed the present guideline: the Endocrine Society (ES), the European Menopause and Andropause Society (EMAS) and the British Menopause Society (BMS).

Four years after publication, ESE’s Clinical Committee will assess the need for, and extent of, a revision of this guideline.

Results of the systematic reviews

Clinical questions, eligibility criteria, and definition of endpoints


At the start of the guideline process, the working group formulated clinical questions regarding treatment of women in menopause (peri- and postmenopause). Many of these had been subject to extensive review in recent years with development of guidelines for practice within Europe (European Menopause and Andropause Society (EMAS)), the UK (National Institute of Health and Care Excellence (NICE), British Menopause Society), the USA (The Endocrine Society, The Menopause Society) and Asia (Indian Menopause Society). Reviews and metanalyses were considered for our guideline and most areas not subject to further extensive review. However, there were three areas where it was considered that further information was needed. These clinical questions formed the basis for the new systematic reviews and are summarized in [Table 1](#).

Randomized controlled trials (RCTs) presenting data on (post)menopausal women were eligible. RCTs presenting data on women with Turner syndrome (not the scope of this guideline) or women with (a history of (breast)) cancer were excluded. Mixed populations of women with natural and surgical menopause were considered, but where possible, data were stratified. Only studies investigating preparations which are currently on the market were included. Patient relevant outcomes were selected, ie, symptoms or events rather than surrogate markers (eg, “fractures” and not “bone mineral density”). Studies reporting on outcomes “sexual function”,

Table 1. Clinical questions.

Clinical question	Search criteria				Papers included (n)	Respective recommendation
	Population	Intervention	Comparison	Outcome		
Question I: What is the efficacy of locally absorbed low dose oestrogen on sexual function, compared to systemically absorbed oestrogen or placebo?	(Peri/post)menopausal women	Locally absorbed low dose oestrogen	Systemically absorbed oestrogen/ placebo (ie, oral or transdermal)	Sexual function	4 ¹⁶⁻¹⁹	R 2.10
Question II: What is the impact of different oestrogen dosages on fracture risk in peri/postmenopausal women?	(Peri/post)menopausal women	Oestrogen dosage A, oestrogen dosage B etc	Comparative, placebo or no treatment	Fractures: hip, vertebral	14 ²⁰⁻³³	R 2.11
Question III: What is the impact of progesterone monotherapy on menopausal symptoms?	Symptomatic (peri/post)menopausal women	Progesterone, synthetic progestogen	Placebo or no treatment	Symptoms of menopause (ie, VMS, QoL, cognition (memory), sleep)	10 ³⁴⁻⁴³	R 2.9

VMS, vasomotor symptoms; QoL, quality of life.

**Figure 2.** Effects of locally absorbed low dose oestrogen and placebo on sexual function, as measured by total FSFI-score.

“symptoms” and “quality of life (QoL)” had to be scored using validated questionnaires.

The follow-up for studies reporting on fracture risk had to be at least 1 year. In case of multiple studies describing the same cohort, the study comprising the highest number of subjects was included. Eligible studies were restricted to languages familiar to the authors (English, French, German, Dutch and Spanish). Authors were contacted for clarification when reported data were not sufficient for accurate data extraction.

Description of search and selection of literature

PubMed, MEDLINE, Embase, Web of Science, and Cochrane Library were searched with the help of a specialized librarian to identify potentially relevant studies. The literature searches for questions I, II and III were performed in September 2023, October 2023 and November 2023, respectively. Searches can

be found in [Appendix 3](#) (see section on [Supplementary material](#)). All studies obtained from the searches were entered into reference manager software (EndNote X21, Clarivate Analytics, Philadelphia, PA) and title and abstract were screened. Potentially relevant studies were retrieved for detailed assessment. References of included studies were assessed for additional relevant articles.

Summary and interpretation of evidence from the systematic reviews

Clinical question I: what is the efficacy of locally absorbed low dose oestrogen on sexual function, compared to systemically absorbed oestrogen or placebo?

There were no RCTs identified comparing locally absorbed low dose oestrogen versus systemically absorbed low dose oestrogen.

Four RCTs were included comparing locally absorbed low dose oestrogen versus placebo in a total of 917 women.¹⁶⁻¹⁹ Various preparations were investigated; oestradiol softgel vaginal insert 4 µg and 10 µg,¹⁶ vaginal oestrogen ring 2 mg,¹⁸ oestradiol 10 µg and oestriol 10 µg in a base cream intravaginally¹⁹ and oestradiol vaginal tablet 10 µg.¹⁷ All studies assessed sexual function after 3 months through the Female Sexual Function Index (FSFI). The FSFI is a validated 19-item, self-reported measure of female sexual function that provides scores on overall levels of sexual function as well as on six primary components of sexual function: desire, arousal, lubrication, orgasm, satisfaction and pain.⁴⁴ Maximum score of the sum of domains is 36, where a higher score indicates better sexual function. For details of included studies and GRADE assessment see [Appendix 4](#). Overall, quality of evidence was low due to a serious risk of bias.

Only one study reported a significant improvement in total FSFI score after three months use of oestradiol softgel vaginal insert 10 µg vs placebo (mean difference 9.43 vs 7.46, $P < .05$), the other three studies found no clear difference (see [Figure 2](#)).

Concerning FSFI domains: an improvement in “lubrication” and “pain” was seen with oestradiol softgel vaginal insert 10 µg and oestriol 10 µg in a base cream intravaginally.^{16,19} Oestriol 10 µg in a base cream intravaginally also improved “desire”.¹⁹

Based on this limited data on small numbers of women, no firm conclusions can be drawn regarding the effect of locally absorbed low dose oestrogen versus placebo on sexual function.

Clinical question II: what is the impact of different systemic oestrogen dosages on fracture risk in postmenopausal women?

Fifteen RCTs were initially included;^{20-33,45} one study was later excluded after publication of an Expression of Concern,⁴⁶ leaving a total of 14 studies comprising 30 910 women included in this review. For details of included studies and GRADE assessment [Appendix 5](#). Overall, quality of evidence was low, due to study limitations (concerns on adhering to intervention and missing outcome data) and imprecision in smaller studies. In addition, most studies included women with a relatively young age, resulting in study populations with a low fracture risk at baseline.

Only two studies assessed the impact of different oestrogen dosages on fracture risk and found no difference in combined MHT containing conjugated equine oestrogen (CEE) 0.625 mg vs 0.3 mg and combined MHT containing 17-β oestradiol 1 mg vs 2 mg, respectively.^{25,33} However, there were no events in both studies, probably due to the relatively young age of included women and moderate length of follow-up.

Vickers *et al.* assessed fracture risk comparing combined MHT to oestrogen alone (CEE 0.625 mg/MPA 2.5/5.0 mg daily vs CEE 0.625 mg daily) and found no clear difference (hazard ratio (HR) of osteoporotic fractures 1.5 (95%CI 0.62-13.72), $P = .35$).³²

The other studies compared various MHT regimens versus placebo, calcium or no treatment; the largest one being the WHI reporting a hazard ratio (HR) of 0.67 (95%CI 0.47-0.96) for hip fractures and HR 0.65 (95%CI 0.46-0.92) for vertebral fractures after daily use of CEE 0.625 mg/MPA 2.5 mg.²⁰ [Figure 3](#) clearly illustrates that fewer women in MHT groups experience total fractures (3A) and hip or vertebral fractures (3B) than in control groups.

Clinical question III: what is the impact of progestogen monotherapy on menopausal symptoms?

Ten RCTs assessing the impact of progestogen monotherapy (ie, MHT including progestogen, but without oestrogen) on menopausal symptoms were included.³⁴⁻⁴³ Study numbers were small, ranging from 10 to 223 women. Details of included studies and GRADE assessment can be found in [Appendix 6](#). Overall, quality of evidence was very low (concerns on randomization process, adhering to intervention and missing outcome data) and imprecision in smaller studies, and results might have been influenced by the placebo effect.

VMS

Nine studies reported on the effects on VMS of progestogen monotherapy (514 women) vs placebo (325 women).^{34,36-43} VMS were measured according to the vasomotor component of the Green Climacteric Scale and/or changes in their frequency and/or severity.

Oral progesterone preparations were used in five studies.³⁷⁻⁴¹ Hitchcock *et al.* reported an improvement in VMS frequency and severity after 3 months oral use of 300 mg micronized progesterone at bedtime,³⁷ but these results could not be confirmed by Prior *et al.*, using the same treatment regimen³⁹ or by Schüssler *et al.*, using the same dosage short-term (3 weeks).⁴¹ In a small cross-over trial ($n = 32$) women reported a decrease of VMS frequency after 3 months use of 20 mg MPA.⁴⁰

Short-term daily use of 5 mg norethisterone did not result in a reduction of hot flush frequency.³⁸

VMS also did not respond to low-dose (5-60 mg daily) transdermal progesterone treatment;^{34,42,43} it is acknowledged that progesterone cream is not well absorbed compared to oral micronized progesterone.

In one study a monthly intramuscular depot of 150 mg MPA was administered during 6 months.³⁶ 89.5% of women in the treatment group reported elimination or significant decrease of hot flushes, vs 25% in the placebo group ($P < .001$).

Sleep

Schüssler *et al.* found no difference in subjective sleep quality in a cross-over trial after daily use of 300 mg oral progesterone or placebo during 3 weeks, however women did not report sleep disturbances at entering the study.⁴¹

Psychological functioning

Three studies, all using transdermal progesterone preparations, assessed psychological functioning through the psychological components of the Green Climacteric Score (GCS) and the Menopause-Specific Quality of Life (MenQoL) questionnaire.^{34,41,42} Stephenson *et al.* reported “significant beneficial changes over placebo $P < .05$ in women using 20 mg transdermal progesterone daily for 4 weeks.⁴² However, no significant effects on psychological functioning were reported by Benster *et al.* after 6 months use of natural progesterone cream in daily dosages ranging from 5 to 60 mg,³⁴ and by Wren *et al.* after 3 months daily use of 32 mg progesterone cream.⁴³

Physical functioning

Above mentioned three studies also assessed physical functioning through the somatic components of the GCS and the




Figure 3B: Veerus (2006), Liu (2005) and Liao (2009): there were no events in treatment and control groups: orange and blue dots overlap. Lufkin (1992) has substantially larger numbers of women with fractures; women with ≥ 1 osteoporotic fracture were included without receiving any other anti-osteoporotic therapy.

Figure 3. Percentages of women with fractures (total fractures: (A), hip or vertebral fractures: (B)).

MenQoL questionnaires.^{34,41,42} No significant effect of progesterone treatment vs placebo on physical functioning was found.

Cognition

Schüssler *et al.* and Berent-Spillson *et al.* performed a range of tests assessing verbal and visual cognitive function in postmenopausal women after daily oral use of 300 mg progesterone during 3 weeks and 200 mg progesterone during 12 weeks, respectively.^{35,41} Apart from a small improvement in verbal memory, no significant improvements were seen in other components of cognition such as visual memory, speed of information processing and attention.

Sexual function

Only one study assessed sexual function and found no major differences on the sexual components of the GCS and MenQoL questionnaire after 12 weeks of treatment with 32 mg progesterone cream vs placebo.⁴³

Adverse effects

Vaginal spotting or bleeding during progestogen treatment was reported by 9.5% of women, compared to 2.1% in the placebo group. Other reported adverse effects were headache (4% progestogen vs 1.5% placebo) and nausea (2.3% progestogen vs 0.3% placebo). A list of all studies including these reported adverse effects can be found in Table S6.

In conclusion, hampered by a relatively small number of included women and heterogeneity in progesterone treatment formulations and regimens, we did not find a consistent beneficial effect of progestogen monotherapy on menopausal symptoms (Table 2).

Recommendations

R 1.1

We recommend that menopause is considered as a spectrum and includes the perimenopause and postmenopause. (Good Clinical Practice)

Menopause, defined as one year after the final menstrual period, is determined retrospectively. It is preceded by the

Table 2. Impact of progestogen monotherapy on menopausal symptoms.

Symptom	Effect
VMS	No consistent beneficial effect of oral progesterone No effect of progesterone cream Beneficial effect of i.m. depot MPA
Sleep	No effect of oral progesterone
Psychological functioning	No consistent beneficial effect of progesterone cream
Physical functioning	No effect of progesterone cream
Cognition	Small improvement in verbal memory after oral progesterone; other components of cognition no effect
Sexual health	No effect of progesterone cream

i.m., intramuscular; MPA, medroxyprogesterone acetate.

perimenopause. This transition may last several years. Symptoms may start during the perimenopause.

The mean age of menopause in Europe is 51 years in Caucasian women. However, the time of starting the perimenopause varies over countries and by race/ethnicity. The absence of menses does not define menopause in all cases. Menses do not occur following hysterectomy and with some types of contraception (eg, intra-uterine progestogens). However, it is important to consider the possibility of perimenopause even in the absence of typical symptoms, particularly in younger women.

The change in biology and ovarian function is gradual and encompasses the perimenopause, and symptoms may start during this time which may require treatment.

R 1.2

We recommend that perimenopause is considered when menstrual irregularity and/or vasomotor symptoms are present, even in younger women (40 to less than 45 years). (Good Clinical Practice)

Menstrual irregularity is described within the STRAW criteria (Figure 1) and is a cycle length that falls outside 21-35 days and may vary from month to month. However, cycle length may decrease during the later years of the reproductive phase.

R 1.3

We recommend that premature ovarian insufficiency is considered in women under 40 years of age in the presence of menstrual irregularity and/or subfertility and/or vasomotor symptoms. (Good Clinical Practice)

Premature ovarian insufficiency (POI) is the loss of ovarian function below the age of 40 years and occurs in at least 1%-3% of women.^{47,48} Most cases of POI are idiopathic although more genetic abnormalities are now being identified using next generation sequencing.⁴⁹ A family history of early menopause is common in women with POI and the age of menopause in the mother is a predictor of age of menopause in the daughter. Secondary causes of POI include genetic (Turner syndrome or its mosaics, Fragile X Messenger Ribonucleoprotein 1 (FMR-1) premutation), autoimmune and infectious causes. An increasing proportion of secondary POI is iatrogenic, resulting from surgical removal of the ovaries, chemotherapy, or pelvic radiation.⁵⁰ POI should be ruled out in women younger than 40 years presenting with cycle

disturbances or oestrogen deficiency symptoms.⁵¹ Whereas biochemical measurements are not required to diagnose menopause in women over 45, the diagnosis of POI is confirmed with one serum follicle stimulating hormone (FSH) >25 IU/L or, in those where the diagnosis is less clear, including some women aged 40 to less than 45 years, when two serum FSH measurements more than 4 weeks apart are >25 IU/L⁵² (see R 1.4 and R 1.5).

Once the diagnosis POI is confirmed, additional investigations include karyotype, additional genetic testing (where available) and FMR-1 premutation screening, adrenal cortex and 21-hydroxylase antibodies, thyroid stimulating hormone, bone densitometry and pelvic ultrasound. Baseline evaluation of women with POI before the commencement of HRT should include fracture risk and cardiovascular disease risk estimation. During long-term follow-up women should be assessed for quality of life, mental, sexual, cardiovascular and bone health. Breast cancer screening should be performed according to national guidelines for the general population.^{53,54} Management and follow-up of women with POI is described briefly later in the guideline and the reader is also referred to the recently updated ESHRE Guideline on POI.⁵⁵

R 1.4

We recommend biochemical testing for diagnosis or management of (peri)menopause in women older than 45 years is not necessary. (Good Clinical Practice)

In the case of typical menopausal symptoms in an otherwise healthy woman of normal menopausal age, no measurement of FSH is required. The increase in FSH may already be present during the late reproductive phase and continues to fluctuate for several years until menopause (Figure 4).⁵⁶ Consequently, a normal FSH for those of fertile age does not rule out (peri)menopause. While anti-müllerian hormone (AMH) is often used to predict response to fertility treatment, it is not yet clearly useful in diagnosing menopause.⁵⁷ AMH is decreasing during the later reproductive years, but age has a greater impact on AMH levels than reproductive stage.

R 1.5

We recommend biochemical testing for the presence of POI in women under 40 years of age in the presence of menstrual irregularity and/or subfertility and/or vasomotor symptoms; biochemical testing for the presence of perimenopause or menopause can also be considered in women aged 40-45 years. (Good Clinical Practice)

POI is life-changing for a woman. A delay in diagnosis may result in long-term physical and mental health implications and a compromised quality of life. Untreated POI is associated with an increased risk of osteoporosis,⁵⁸ cardiovascular disease,⁵⁹ cognitive decline,⁶⁰ depression⁶¹ and sexual dysfunction.⁶² Early diagnosis is important so that management can be instituted promptly. Therefore, evaluation of menopause/perimenopause should be performed in all women <40 years as well as some aged 40 to less than 45 years old presenting with menstrual irregularity, unexplained subfertility or menopausal symptoms.

Women with early menopause (menopause <45 years) share common risks with women with POI. Although not always as high as the risk of women with POI, the risk of cardiovascular disease,⁶³ osteoporotic fractures,⁶⁴ dementia,⁶⁰ as




Figure 4. (Peri)Menopausal FSH, LH and AMH values. *Hum Reprod Update*, Volume 29, Issue 3, May-June 2023, Pages 327-346, <https://doi.org/10.1093/humupd/dmac045>. FSH, follicle-stimulating hormone; LH, luteinizing hormone; AMH, anti-müllerian hormone.

well as all-cause mortality⁶³ is increased in women with early menopause compared to women who experienced menopause at an age older than 45 years. It is therefore suggested that menopause may also be investigated in women aged 40 to less than 45 years who present with symptoms suggestive of perimenopause.

R 1.6

If biochemical testing for perimenopause is considered, we suggest measuring FSH at day 2 to 5 of the menstrual cycle or after an interval greater than 40 days without menstruation. (Good Clinical Practice)

Circulating FSH fluctuates during the menstrual cycle and is lowest in the early follicular phase and rises to a maximum level of about 20 IU/L at ovulation. An FSH value greater than 25 IU/L in early follicular phase or in women with amenorrhoea/oligomenorrhoea is strongly suggestive of perimenopause although it is difficult to define a specific value⁶⁵ Thus oestradiol should be measured with FSH in order to interpret the result. Although not diagnostic of perimenopause, low levels of AMH and oestradiol in combination with a high level of FSH support perimenopause. Given the fluctuation of FSH, a second measurement of FSH 4-6 weeks later may be required, particularly if pregnancy risk is an issue.

R 1.7

We recommend that, when the medical history and clinical presentation of a woman of reproductive age include interference with the menstrual cycle and/or lead to menopause-like symptoms, other diagnoses should be considered. These may require additional testing. (Good Clinical Practice)

Pregnancy should be considered in women with amenorrhoea of less than 12 months. Thyroid disease (hyper- or hypothyroidism) and hyperprolactinemia can cause menstrual irregularities or amenorrhoea; the work-up might thus include thyroid function and prolactin measurement. Functional hypothalamic amenorrhoea (FHA) and polycystic ovary syndrome (PCOS) are two syndromes associated with amenorrhoea that are important to differentiate since the aetiologies

and treatments differ. FHA, a neuroendocrinopathy and the cause of about one-third of cases of secondary amenorrhoea, is typically the result of psychosocial stress, over-exercising and/or disordered eating. The condition can be identified in women with at least three consecutive months of amenorrhoea and low oestradiol, luteinizing hormone (LH) and FSH levels, normal or low LH/FSH ratio as well as low testosterone levels. In contrast, PCOS is frequently associated with an increased LH/FSH ratio and elevated testosterone levels.⁶⁶ AMH levels are used to discriminate PCOS from other causes of oligomenorrhoea or amenorrhoea.

R 1.8

We recommend that all women with POI are referred to a menopause expert and where possible, a multidisciplinary team. (Good Clinical Practice)

This should include a clinician with specialized knowledge and expertise in the area, understanding the biological, psychological, and social aspects, which should help to avoid delayed diagnosis and facilitate appropriate treatment and also psychologists, physicians with expertise in bone and cardiovascular health, and a gynaecologist. Fertility issues will also need to be considered in some individuals. Oncologists can be consulted as cancer treatments (surgery, radiotherapy and chemotherapy) can induce POI and some cancers are hormone dependent, but others are not.⁶⁷

POI is a multidisciplinary disease with life-changing physical and psychological impacts for women of reproductive age requiring lifelong management. It is important to avoid delay in diagnosis (see R 1.5) and start appropriate treatment early.⁵⁸

HRT should aim at restoring oestrogen levels to the premenopausal state and should be prescribed to all women with POI irrespective of the presence of menopausal symptoms unless there is a contraindication for HRT such as hormone dependent cancer. The HRT regimen should be determined based on clinical history and comorbidities. Vaginal oestrogens may also be needed for women who still have symptoms of vulvovaginal atrophy while on systemic HRT. Women on HRT who have symptoms suggestive of hypoactive sexual desire disorder (HSDD) may be candidates for systemic

testosterone therapy.⁵⁰ HSDD in postmenopausal women is the only evidence-based indication for testosterone therapy. Doses should aim at premenopausal physiological testosterone levels. The transdermal route is preferred because of its neutral effect on the lipid profile. Short-term safety data are reassuring, however the long-term safety of testosterone therapy warrants further investigation. For more details about dosages and monitoring we refer to the publication of Davis *S et al*, 2019⁶⁸

Quality of life, bone, metabolic, cardiovascular, mental and sexual health should be monitored regularly. Sexual dysfunction, depression, dyslipidaemia, diabetes, hypertension and osteoporosis should be investigated and treated, with referral to a specialist if needed.⁵⁰

In contrast to natural menopause, intermittent ovarian function might occur in women with spontaneous POI. Ovulatory cycles might occur in up to 25% of women, however, the chance of spontaneous pregnancy is small (1%-10%). Women not desiring pregnancy should use contraception, as HRT is not a contraceptive. FMR-1 premutation carriers should receive preconception counselling. Oocyte donation is an established option for fertility in women with POI. Women desiring pregnancy should be referred to a specialist in reproductive endocrinology.⁶⁹

R 1.9

We suggest that where possible, women in perimenopause, who are under the age of 40 and have apparent contraindications for HRT, are referred to a unit with particular expertise in managing such women. These include, for example, women with a history or high risk of a hormone dependent cancer, thrombotic or cardiovascular high risk, women who have an inadequate response to hormone therapy or those who have significant adverse effects

Women with POI or apparent contraindications for HRT, should be referred to an appropriate unit with particular expertise. This will allow detailed consideration of the risks versus benefits of treatment for each woman.

Women experiencing inadequate response and/or adverse effects related to HRT should also be referred to menopause specialists. In most cases, changing the HRT route of administration and/or dosage is sufficient to improve symptoms in the long-term (see also 2.6). Women should be supported to make a personalised decision on managing their menopause symptoms. Alternatives to pharmacological therapy are available (Table 3).⁷⁰ Cognitive behavioural therapy has high quality evidence from multiple RCTs supporting its use for menopause,^{65,66,96,97} so provides an alternative where women are unable to have pharmacological treatment. Hypnosis also has RCT evidence showing reduction in multiple menopause symptoms.^{98,99} Other complementary therapies with psychological benefit have been studied, but with less consistent results or with weaker evidence.^{67,68,100-111} Plant-based derivatives for menopause may be widely purchased without prescription and provide options to support women in their healthcare. However, the quality of evidence supporting their use is generally weak or inconclusive.^{69-72,112} In addition, some products may contain compounds with estrogenic activity or may interact with anticancer therapies (About Herbs, Botanicals & Other Products | Memorial Sloan Kettering Cancer Center). There may also be other herb- drug and herb-

herb interactions.¹¹² We consider that diabetes is not a contraindication for MHT unless poorly controlled (see R 3.4).

SECTION 2: general introduction to treatment with MHT/ HRT

Diagnostic protocol prior to MHT/HRT introduction

Before introducing any type of hormone therapy (MHT or HRT), it is necessary to determine the indication and the presence of absolute or relative contraindications in order to create a tailored approach that will be the safest and most effective. A detailed medical history is essential, with a focus on possible contraindications or drug interactions. Patients must be asked about symptoms, comorbidities (thromboembolic events, metabolic diseases, osteoporosis and fractures, psychiatric health), reproductive health including contraceptive needs and menstrual cycle characteristics (bleeding patterns, regularity and any abnormal uterine bleeding), medication use, surgeries, allergies and lifestyle factors (diet, smoking, alcohol use). A detailed family history should include a history of cancers, particularly breast, uterine, ovarian, and colon, and cardiovascular disease/risk factors. A general examination should include weight and blood pressure; gynaecological examination is not necessary before starting MHT if the patient is without additional gynaecological symptoms although, in some countries pelvic, breast and thyroid examination may be performed, depending on the screening protocols for breast and cervical cancer or the presence of relevant symptoms.

Essential components and recommendations are listed in Table 4.

Prescribing of hormone therapy should be in the context of a woman's personal and family history (understanding her risk factors), symptoms, treatment goals and values, and current screening. Assessment will be based on individual risk factors; additional blood tests may be requested. Indication for bone mineral density measurement (BMD) depends age, risk factors and according to availability/costs of services.

R 2.1

We recommend that a holistic approach is taken for women during perimenopause and menopause, not having a sole focus on HRT/ MHT. (Good Clinical Practice)

Menopause occurs in the context of a woman in midlife and all that this entails. Women commonly have clusters of menopause symptoms which can be characterized,¹¹⁹ and treatment regimens should be personalized to address individual needs. Thus, we cannot consider therapeutic options for singular symptoms without considering the entirety of the person experiencing these symptoms. For example, women are important contributors to the global economy, and menopause symptoms impact a woman's ability to be fully present at work and to participate in the workforce¹²⁰ for the duration that she chooses rather than one that is dictated or influenced by the severity of menopause symptoms that she may (or may not) experience. In addition, race, ethnicity and social economic status appear to influence the experience of menopause,¹²¹ likely due to disparities in social determinants of health. Thus, the therapeutic approach should include not only symptom management, but also an assessment of general health and the psychosocial factors influencing health, as treatment of menopause symptoms will impact a woman's quality of life and subsequently her ability to engage in lifestyle

Table 3. Alternative non-pharmacological treatments.

Treatment	Type of evidence considered	Reported benefits
Therapies associated with psychological benefits		
Cognitive behavioural therapy	RCT	Reduced hot flash distress or interference but not frequency ⁷¹⁻⁷³ Improved symptoms of depression and anxiety also reported ^{72,74}
Hypnosis	RCT	Reduction in vasomotor symptoms ⁷⁵ Improved sleep quality and sexual function ^{75,76}
Biofeedback	Systematic review	Positive effect on menopause symptoms and stress, but low quality evidence and inconsistent results noted in systematic reviews ^{77,78}
Relaxation techniques	RCT	Inconsistent effect reported on reduction in vasomotor symptoms ⁷⁹⁻⁸¹
Mindfulness-Based Stress Reduction	RCT	No improvement in vasomotor symptoms ^{82,83} May reduce stress and anxiety, and improve sleep quality and quality of life ^{82,83}
Yoga	Systematic review	No improvement in vasomotor symptoms ⁸⁴ Improvement in psychological symptoms of menopause ⁸⁴
Aromatherapy	RCT	Improved vasomotor and psychological symptoms ⁸⁵⁻⁸⁸
Physical activity	Systematic review and meta-analysis	Significant effect on vasomotor symptoms severity, mixed results concerning frequency ^{89,90}
Ingestion of plant-based derivatives		
Black cohosh	Systematic review	No significant effect on vasomotor symptoms ⁹¹ Further studies needed to investigate effects on other menopause symptoms
Evening primrose oil	RCT	No or minor (non-clinically significant) reduction in vasomotor symptoms ^{92,93}
Phytoestrogens	Systematic review	No conclusive evidence of reduction in vasomotor symptoms ⁹⁴ Strong placebo effect observed
Maca (<i>Lepidium meyenii</i>)	Narrative review	Potential improvements in menopause symptoms but insufficient to recommend usage ⁹⁵
Pollen Extract		
Dong Quai (<i>Angelica sinensis</i>)		

modifications which may impact and reduce her risk for chronic diseases. Therefore, menopause management, the use of MHT, and chronic disease prevention should be considered in the context of the individual woman. Women should be counselled on strategies for chronic disease prevention, including the importance of a healthy diet, regular exercise, adequate sleep, stress management, and avoidance of tobacco and excessive alcohol use. Increasing age and the perimenopause have also been identified as risk factors for cardiovascular disease (CVD),¹²² making CVD risk assessment and modification of risk factors for CVD essential as part of a clinical visit for midlife women.

R 2.2

We recommend that women in peri- and post-menopause who are appropriate candidates for MHT can be managed in primary care according to recognized guidelines

There is a large evidence base regarding the risks and benefits of MHT and the profile is well-established. If health care professionals are uncomfortable with managing menopause symptoms, communication with an expert should be considered since this may avoid the need for referral.

R 2.3

We recommend that before starting HRT/MHT women are well-informed about the benefits and risks of treatment and other options in order to facilitate shared decision making. (Good Clinical Practice)

Initiation of MHT requires a comprehensive discussion of potential risks and benefits, taking into account a woman's medical and family histories as well as her personal preferences. Shared decision-making is an important component of this dialogue. Considering these factors, MHT use, including the

formulation, dose and route of administration as well as the duration of therapy can be individualized.

R 2.4

We recommend, if indicated, in women with a uterus, to start MHT with a preparation combining oestrogen and progestogen. (⊕⊕⊕⊕)

Oestrogen therapy alone, when not balanced by a progestogen or progesterone, can stimulate the growth of the endometrium, increasing the risk of abnormal uterine bleeding, endometrial hyperplasia and cancer.¹²³ The risk of endometrial cancer increases with oestrogen treatment alone dependent on dose and duration of treatment (OR/HR 1.45-4.46),¹²⁴ while oestrogen in a continuous combined regimen with progestogen even reduces the risk of endometrial cancer (OR/HR 0.24-0.72).¹²⁴ Consequently, women who have not had a hysterectomy should also be prescribed a progestogen to provide endometrial protection.¹²⁵ For low-dose vaginal oestrogen, a progestogen is not indicated; however, endometrial safety has not been studied in clinical trials beyond one year.¹²⁶

Systemic oestrogen can be administered orally or through transdermal patches, spray, gels, and implants. The availability of these different preparations varies within and between countries. In Europe, administration of oestradiol is preferred over administration of conjugated equine oestrogens (CEE) as being body identical and therefore more "natural". Different progestogens exhibit different effects on the endometrium, the breast and the cardiovascular system.¹²⁷ MHT can be administered in a continuous combined regimen where both oestrogen and progestogen are given daily. When a cyclic scheme is preferred, women with an intact uterus should receive a progestogen for 12-14 days every month to protect the endometrium and ensure withdrawal bleeding. Table 5 gives an overview on various available MHT/HRT preparations and

Table 4. Clinical assessments prior to introduction of HRT/MHT¹¹³⁻¹¹⁸.

Medical history	Blood tests	Additional investigations	Follow up
Menopausal symptoms (VMS, sleep, mood disorders)	<i>Desirable for general health assessment:</i>	Weight/height	<i>Check-in after 3 months, thereafter 1-2 year basis:</i>
Comorbidities		Waist circumference	
Menstrual cycle characteristics (bleeding patterns, regularity)	Complete blood count	Blood pressure	Evaluation of symptoms
Medications (past and current) and supplements	Fasting blood glucose	<i>If indicated:</i>	Blood pressure
Lifestyle factors, including social determinants of health	Renal function	Pelvic/breast examination	Changes in health status (risk/benefit profile)
Personal history; emphasis on past obstetric history, parity, mode of delivery, (gynaecological) surgeries, CVD, osteoporosis, cancers	Liver function	Thyroid examination	
	Lipid status (may depend on the country's policy)	Mammography	
Family history; mothers' age at menopause, CVD, osteoporosis, cancers	<i>Optional:</i>	Bone densitometry	
	FSH (<45 years)	Pap smear/HPV screening	
	Thyroid function		
	Vitamin D		
	Additional evaluation for those with POI is often undertaken (see section on POI)		

VMS, vasomotor symptoms; CVD, cardiovascular disease; FSH, follicle-stimulating hormone; POI, primary ovarian insufficiency; HPV, human papilloma virus.

whether a sequential or continuous combined regimen is preferred. The potential benefits of so-called “bioidentical hormone therapy”, often used to promote non-licensed compounded hormone therapy, can almost always be achieved using conventionally licensed products that contain ‘body identical hormones’ unless there is an intolerance or allergy. These include oestradiol, progesterone, and testosterone. This flexibility in licensed treatment options empowers health-care professionals to find the best solution for each patient supported by extensive clinical trials. Compounded non-government approved bioidentical hormone therapies prepared by a compounding pharmacist using a provider’s prescription may combine multiple hormones (oestradiol, oestrone, oestriol, dehydroepiandrosterone, testosterone, progesterone) and may be administered in nonstandard or untested routes, such as subdermal implants, pellets, or troches.

These compounded bioidentical therapies lack adequate safety, efficacy, and high-quality pharmacokinetic data to provide adequate evidence of safety and efficacy. There is insufficient evidence to support the overall clinical utility and safety of compounded bioidentical hormone therapy for the treatment of menopause symptoms.¹²⁸

Consider compounded bioidentical hormone therapy only if intolerance to a government-approved therapy, such as an allergic reaction or a medical need for a non-government-approved dose or formulation. Documentation should include medical indications for compounded bioidentical hormones over government-approved therapies.¹²⁸

Micronized progesterone, given in an oral dose of 200 mg/day for 12 days per 28-day cycle was as effective as the same regimen using 10 mg/day medroxyprogesterone acetate (MPA), or 2.5 mg MPA/day for 28 days. The outcome assessed was the avoidance of endometrial hyperplasia which followed administration of 0.625 mg/day CEE¹²⁹ alone. These data on the safety of progesterone on the endometrium were supported by more recent studies although limited to 1 (or 2) years in length.^{127,130}

In addition, considering breast and cardiovascular safety profiles, micronized progesterone or dydrogesterone appear to be most favourable.^{35,131} Current evidence does not suggest that micronized progesterone or dydrogesterone increase the risk of venous thrombosis and maybe associated with a lower

risk of breast cancer compared to that noted with other oral progestogens.¹³² Finally, the levonorgestrel-releasing intra-uterine device provides contraception and protection against endometrial hyperplasia; its activity lasts 5 years.¹³³

In some countries, a combination oestrogen/selective oestrogen modulator (SERM) is available as MHT without a progestogen which combines CEE with the SERM bazedoxifene to treat VMS, maintain bone density. In trials up to 2 years, no increase was seen in breast tenderness, breast density, or bleeding compared to placebo and significantly less than with an active comparator conjugated equine oestrogen with medroxyprogesterone acetate.¹³⁴⁻¹³⁶

R 2.5

We recommend, if indicated, in women without a uterus, to start MHT with a preparation with oestrogen alone. (⊕⊕⊕○)

Oestrogens are administered as monotherapy in women who have had a hysterectomy and are similarly effective on vasomotor symptoms.¹³⁷ There is no therapeutic benefit in administering a progestogen to women who have had a hysterectomy as progestogens are used to oppose oestrogen stimulation of the endometrium, except in cases of endometriosis. Therefore, although beyond the scope of this guideline, in women with a history of endometriosis, starting with a combination of oestrogen and progesterone or tibolone can be considered, regardless of whether they still have their uterus. Oestrogens, particularly conjugated equine oestrogen alone has been shown to have less impact on the risk of breast cancer compared to the combined oestrogen/progesterone regimen and varies by the type of progesterone used (see R 3.8).¹³⁸

R 2.6

We recommend that in women treated with MHT for symptoms, treatment effects should be re-evaluated after 3 months. In case of an inadequate response, adverse effects or intolerability, dose and formulation should be re-evaluated. (Good Clinical Practice)

Depending on the response of symptoms to dose and individualized risk factors, the dose of hormone therapy can be adjusted after a trial of 3 months (Figure 5: Evaluation and

Table 5. MHT/HRT preparations and regimens this table refers to women with natural menopause as young women (ie, those under 40 years) may require higher doses of HRT.⁵⁵ This may vary with availability of preparations in different countries.

	Lowest dose	Highest dose (MHT)	Safe high dose (HRT)	Equivalent doses
ORAL OESTROGEN (<i>always use with progestogen in women with uterus</i>)				
Oestradiol valerate	0.5 mg	2 mg	4 mg	2 mg E2 valerate =
Oestradiol hemihydrate	0.5 mg	2 mg	4 mg	0.625 mg
17 β oestradiol	0.5 mg	2 mg	4 mg	conjugated
Conjugated oestrogen	0.3 mg	1.25 mg	1.5 mg	oestrogen
Conjugated oestrogen/ bazedoxifene ^a	conjugated oestrogen 0.45 mg / bazedoxifene 20 mg	conjugated oestrogen 0.45 mg / bazedoxifene 20 mg	-	
Oestrinol	1 mg	2 mg	2 mg	
TRANSDERMAL OESTROGEN (<i>always use with progestogen in women with uterus</i>)				
Oestrinol	0.5 mg	2 mg	2 mg	4.59 mg E2H skin
Oestradiol hemihydrate skin spray	1.53 mg/1 spray	4.59 mg/3 sprays	4.59 mg/3 sprays	spray
Oestradiol hemihydrate gel	0.5 mg	1.5 mg	1.5 mg	= 1.5 mg E2H gel
Oestradiol hemihydrate skin patch	25 mcg	100 mcg	100 mcg	= 100 mcg E2H skin patch
Colour legend				
Oral synthetic oestradiol				
Transdermal oestradiol				
Natural oestradiol				
Natural progesterone				
(dydrogesterone is considered a natural since it is an isomer)				
Synthetic progestogen				
Equivalent dose				
	Lowest dose	Highest dose (MHT)	Safe high dose (HRT)	Equivalent doses
SEQUENTIAL PROGESTOGEN (<i>from day 12 to day 26 of menstrual cycle</i>)				
Micronized progesterone	200 mg	300 mg	300 mg	200 mg micronized
Dydrogesterone	10 mg	10 mg	15 mg	P4
Norethisterone acetate	1.25 mg	5 mg	5 mg	=
Transdermal norethisterone acetate	0.140 mg/day	0.250 mg/day	0.250 mg/day	10 mg
Medroxyprogesterone acetate	5 mg	10 mg	10 mg	
CONTINUOUS PROGESTOGEN (<i>daily</i>)				
Micronized progesterone	100 mg	200 mg	200 mg	dydrogesterone
Dydrogesterone	2.5 mg	10 mg	10 mg	=
Norethisterone acetate	0.1–0.5 mg	2.5 mg	2.5 mg	5 mg norethisterone acetate
Transdermal norethisterone acetate	0.140 mg/day	0.250 mg/day	0.250 mg/day	=
Medroxyprogesterone acetate	5 mg	10 mg	10 mg	10 mg MPA
Drospirenone	2 mg	2 mg	2 mg	
Tibolone	2.5 mg	2.5 mg	2.5 mg	
Levonorgestrel (patch with oestradiol)	0.015 mg/day	-	-	
Levonorgestrel intrauterine device	20 mcg/day	-	-	

^aNot to be combined with progestogen, since the bazedoxifene component reduces the risk of endometrial hyperplasia that can occur with the conjugated oestrogens component.

E2, oestradiol; E2H, oestradiol hemihydrate; P4, progesterone; MPA, medroxyprogesterone acetate

treatment algorithm). If the response is inadequate with persistent symptoms or there are adverse events or difficulty tolerating either the oestrogen or progestogen, the dose can be adjusted in accordance with the licensed range (depending on the country). Intolerance of a route of administration or a type of oestrogen or progestogen can be handled by trying a different route of administration or type of therapy, as there are many licensed options available to women.

This flexibility in licensed treatment options empowers healthcare professionals to find the best solution for each patient supported by extensive clinical trials. Approved hormone therapy, including oestradiol, oestrone, and micronized progesterone, is often known as body identical therapy and is regulated and monitored for purity and efficacy, dispensed with package inserts containing extensive product information, and includes adverse events.

The optimal duration of systemic MHT should be determined considering ongoing benefits, potential risks and personal preferences. The limited evidence available does not indicate whether it is better to taper down or to stop abruptly, and likewise there is no convincing evidence regarding the duration for which MHT should be taken.¹³⁹ In other words, limits on duration of use are arbitrary. Treatment should continue for as long as the woman and her GCP feel that benefits outweigh the risks for her.¹³⁹ Vaginal low-dose oestrogen preparations for women with genitourinary symptoms can be continued long-term. Data on safety profiles for breast, endometrial and cardiovascular health are reassuring.¹²⁶ Women with POI should receive HRT at least until the average age of menopause, which is 51 years in mainly White populations, and then be reevaluated periodically.⁵⁵

R 2.7

We recommend taking into account individual characteristics and comorbidities when prescribing MHT and also, preference, availability and costs when choosing between transdermal and oral preparations. (Good Clinical Practice)

The following women can be considered for MHT since they are considered low risk for major adverse cardiovascular events with initiation of MHT for the treatment of menopausal symptoms.¹⁴⁰

- under 60 years of age or within 10 years of menopause onset,
- have a 10-year estimated atherosclerotic cardiovascular disease risk less than 5% using locally accepted risk calculation charts.
- do not have an increased risk of breast cancer or personal history of VTE
- those with an increased risk of VTE or intermediate risk of CVD (eg, obese, controlled diabetes, older women) should be prescribed transdermal oestradiol

However, in the USA and in Europe over 50% of women over age 55 years have at least one chronic medical condition,¹⁴¹ which makes decision-making around MHT more complex. This guideline provides recommendations considering several risks and benefits accompanying MHT use taking individual characteristics and comorbidities of the women into account.

R 2.8

We recommend HRT in POI irrespective of the presence of vasomotor—or other climacteric symptoms as the multimodal benefits clearly exceed the risk. HRT should be continued until the anticipated age of natural menopause and then the ongoing prescription reevaluated periodically. (Good Clinical Practice)

POI is associated with an increased risk of type 2 diabetes mellitus,¹⁴² cardiovascular disease,⁵⁹ osteoporosis⁵⁸ and cognitive decline.⁶⁰ Unless contraindicated, HRT should be recommended for all women with POI and preferably, prescription continued at least until the age of anticipated menopause (for references see ESHRE Guideline on POI⁵⁵). Oestrogen replacement aims to restore serum oestradiol levels towards the range of the mid-follicular phase. Women with an intact uterus should receive a progestogen for 12–14 days every month to protect the endometrium and ensure withdrawal bleeding or a continuous combined regimen.⁵⁰ HRT has not been shown to increase the risk of breast cancer in women under 50 years beyond the age-adjusted risk of normally menstruating women.⁶⁵

R 2.9

We recommend initiating MHT in women within 10 years of natural menopause onset or under 60 years for bothersome menopausal symptoms such as vasomotor or other climacteric symptoms. (⊕⊕⊕○) Women should also be informed that MHT prevents bone loss and reduces fracture risk and may have positive effects on the cardiovascular system. (Good Clinical Practice)

VMS consisting of hot flashes and night sweats have been associated with poor health outcomes,^{143,144} cardiovascular risk

burden,¹⁴⁵ poor sleep quality, reduced quality of life,¹⁴⁶ irritation, bone loss¹⁴⁷ and difficulty in concentration. However, despite VMS being the most common clinical feature of perimenopause and menopause (75% occurrence) and the most common reason menopausal women seek medical attention,¹⁴⁶ it is estimated that only 25% or less of these women are prescribed MHT.¹¹⁶

Although VMS may start during the perimenopause, the most severe VMS appear within 1–2 years after the final menstrual cycle and can last up to 12 years in 10% of cases.^{148–150} The average persistence of VMS is around 7.4 years, with the higher frequency of VMS associated with increased cardiovascular, bone and cognitive risks.^{151–154}

The extent of the reduction in coronary and all-cause mortality associated with taking MHT in a low-risk population is under debate. Some studies suggest significant benefit^{155–159} but it is not currently advised to introduce MHT for the sole purpose of primary or secondary prevention of cardiovascular disease/coronary artery disease. Further information is included below R 3.3. For effects on bone, see R 2.11.

Different pharmacotherapeutic agents are proven to be effective for treating VMS, however, MHT remains the most effective.¹⁶⁰ Standard dose or low dose MHT (CEE 0.3 mg; oral 17β oestradiol ≤0.5 mg; or oestradiol patch 0.025 mg) have proven to be very effective for VMS treatment¹⁶¹ with reduction of the incidence of hot flashes by 75% and their severity by 87%.¹³⁷ Progesterone and progestogens (MPA, megestrol acetate) have also been proven effective for VMS treatment (see **Clinical Question III**) with lesser efficacy but possibly lower risk of breast cancer.¹⁶² In case of MHT cessation, VMS recur in 50%–87%, but usually in lower intensity¹⁶³ with no difference in recurrence rate between sudden or gradual discontinuation.¹⁶⁴ It is not known yet whether the treatments differ in their impact on associated cardiovascular risks.¹⁶⁰

There are other pharmacological treatments for VMS including those acting through the KNDy neurons (NK-3 and NK-1,3 receptor blockers, the SSRIs, SSNIs, Gabapentin, Oxybutinin; see¹⁶⁵ for an overview), fezolinetant and elinzanetant which have been found effective in phase 3 RCTS.^{166,167} Also, non-pharmacological treatments for VMS are available and are listed in [Table 3](#) above.

R 2.10

We suggest that for women with symptoms of vulvovaginal atrophy local or systemic MHT can be considered depending on the presence of other symptoms. Local oestrogen is usually started alone but can be administered with systemic MHT if needed. (⊕⊕○○)

Menopause is associated with sexual dysfunction, dyspareunia, decreased libido and lubrication and an overall decrease of sexual satisfaction.^{168–170} Symptoms of vulvovaginal atrophy (VVA) including vaginal dryness, burning, itching and dyspareunia are caused by oestrogen deficiency and affect about 50% of postmenopausal women.¹⁷¹ VVA is part of the genitourinary syndrome of menopause (GSM), which is also associated with urinary tract problems, such as frequent urination, urge incontinence and recurrent urinary tract infections.¹⁷² Symptoms of VVA may be lifelong and can have a major impact on interpersonal relationships and quality of life.¹⁷³

Systemic MHT or local vaginal oestrogen may ameliorate sexual symptoms due to VVA¹⁷⁴ (see **Clinical question I**), however unless it arises from the relief of VVA, it does not




Figure 5. Evaluation and treatment algorithm. POI, premature ovarian insufficiency; FSH, follicle-stimulating hormone; HRT, hormone replacement therapy; MHT, menopausal hormone therapy. *consider additional biochemical testing for diagnoses other than menopause when a woman's medical history and clinical presentation are suggestive of other causes of menstrual cycle irregularities and/or menopause-like symptoms (see Table 6 on differential diagnosis). ** see Table 4 for possible assessments before introducing MHT. *** see Table 5 for available hormonal preparations.

generally have an effect on sexual interest, arousal and orgasmic response.¹⁷⁵ In menopausal women with low libido, transdermal oestrogen therapy may be preferred, due to the fact that oral MHT can increase sex hormone binding globulin (SHBG) and a decreased testosterone bioavailability.^{174,176} Androgen replacement therapy is also available in some countries although not in Europe. It is therefore not routinely recommended before conventional MHT has been tried.⁶⁸ No matter which modality of androgen therapy is used in menopausal women, it results in testosterone level increase¹⁷⁷

although this should not exceed the physiologic levels found in a premenopausal women.

R 2.11

We suggest that in women without symptoms of perimenopause/ menopause who are under 60 years of age, MHT initiation might be considered for bone protection. (⊕⊕○○)

Postmenopausal osteoporosis primarily results from long-term oestrogen deficiency, leading to accelerated bone loss.

Table 6. Differential diagnosis for POI and early menopause. The conditions listed below may present in a similar way in some instances.

Conditions interfering with menstrual cycle	Vasomotor symptoms differential diagnosis
SECONDARY TO ENDOCRINOPATHIES	SYSTEMIC DISEASES
Functional hypothalamic amenorrhoea (intensive physical activity, restrictive eating, stress) (in up to 3%-4% of the female population ^{96,97})	Hyperthyroidism (in up to 2% in the female population ¹⁰⁰)
Thyroid disorders (hyper-/hypothyroidism) (in up to 4% of the female population ⁹⁸⁻¹⁰⁰)	Allergies and immunological diseases (eg, systemic mastocytosis)
Prolactinoma (or other pituitary tumours) (in up to 0.03% in the female population ¹⁰¹)	Mood disorders (eg, generalized anxiety disorder, panic disorder)
Polycystic ovary syndrome (in up to 13% of the female population ¹⁰²)	Obstructive sleep apnea syndrome (in up to 12% of the female population ¹⁰⁴)
Adrenal tumours (Cushing syndrome, pheochromocytoma, adrenocortical carcinoma)	Rosacea (in up to 5.9% of the female population ¹⁰⁵)
Nonclassical congenital adrenal hyperplasia (in up to 1% of the female population ¹⁰³)	Pheochromocytoma (in less than 0.03% of the female population ¹⁰⁶)
METABOLIC	Acromegaly (in less than 0.01% of the female population ¹⁰⁷)
Eating disorders or gastrointestinal/malabsorption disease (anorexia, bulimia, drastic weight gain, obesity, celiac disease) (in up to 9% of the female population ¹¹⁰)	Medullary carcinoma (in up to 0.03% of the female population ¹⁰⁸)
Systemic illness and weight loss (cancer, infections)	Carcinoid tumours (in less than 0.01% of the female population ¹⁰⁹)
MISCELLANEOUS	Infectious etiologies (TBC, HIV)
Pregnancy	Malignancy (lymphoma)
Cancer treatment	MEDICATIONS
Postsurgical complications (eg, Asherman syndrome) (in up to 5% of the female population ¹¹¹)	Gonadotrophin-releasing hormone agonists (eg, leuprolide)
Environmental factors and professional exposure (shift workers)	Clomiphene
Drug induced (eg, antidepressants, neuroleptics, metoclopramide)	MOA
	Tricyclic antidepressants
	Ca-channel blockers
	SSRI
	Chemotherapy
	Opiates
	Systemic antimycotics
	Aromatase inhibitors
	SSNR
	Food additives (monosodium glutamate, sulfites)
	Diaphoretic drugs Microsoft Word—Diaphoretic_Drugs_2009 2.doc

MOA, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; SSNR, serotonin-norepinephrine reuptake inhibitor.

Controversy abounds about whether MHT should be used first line to prevent or treat osteoporosis and its effectiveness and safety if used to prevent osteoporotic related fractures.

RCTs demonstrate prevention of bone loss in postmenopausal women who did not have significant bone loss or osteoporosis.^{20,178} Many oral and transdermal oestrogen preparations, alone or combined with progestogens, the selective oestrogen receptor modulator bazedoxifene with conjugated equine oestrogens (CEE), and tibolone, have been approved in various countries to prevent osteoporosis.^{179,180} Oral and transdermal oestrogen therapies appear to have similar effects on bone mineral density (BMD).¹⁸⁰ Lower-than-standard doses of oestrogen with and without progestogen have shown improvements in BMD but lesser improvement than standard dose.¹⁸⁰ Based on observational data, women who experience POI are recommended to take MHT until the age of natural menopause to reduce the risk of osteoporosis.¹⁸⁰ Relatively rapid bone loss and loss of protection from fracture occur after discontinuation of hormone therapy,¹⁸¹ which can be prevented by switching to a bisphosphonate or another antiresorptive agent.¹⁸² No rebound fractures were seen in the Women's Health Initiative RCTs after stopping MHT.¹⁸³ The potential bone benefits of hormone therapy should be weighed against the reported risks.¹⁸⁴

MHT is not considered a first line treatment for postmenopausal women with established osteoporosis. In the Women's

Health Initiative (WHI) trial, in women not selected on the basis of bone density or osteoporosis, oestrogen alone or combined with progestin reduced the overall risk of clinical fracture (oestrogen alone hazard ratio [HR] at 7 years, 0.71; 95% CI, 0.64-0.80 and oestrogen/progestin: HR at 5 years, 0.76; 95% CI, 0.69-0.83) and hip fracture (oestrogen: HR at 7 years, 0.65; 95% CI, 0.45-0.94 and oestrogen/progestin: HR at 5 years, 0.67; 95% CI, 0.47-0.96) compared with placebo.^{20,178} The quality of fracture evidence from the WHI is limited by enrolment of fewer women ages 50-59 at baseline (2357 Oestrogen/progestin and 1674 oestrogen alone)¹⁸⁵ when women are most likely to consider hormone therapy to relieve vasomotor symptoms. In addition, the WHI study was not designed to study osteoporosis, and excluded women with prior osteoporotic related fracture being treated with hormone therapy, thus excluding many women with severe osteoporosis; thus, the risk-benefit profile for these women is less certain.¹⁸⁴ In the prospective cohort Million Women Study,¹⁸⁶ current users of hormone therapy (all types, formulations, and routes of administration with oestrogen alone or oestrogen combined with progestogen) were found to have a significantly lower risk of fracture than nonusers (RR 0.62, 95% CI 0.58-0.66). The protective effect was seen for all types of MHT. In addition, a systematic literature review performed in this guideline clearly illustrates that fewer women in MHT groups experience total fractures and hip or vertebral fractures than in control groups (Figure 3).

In a pooled analysis from phase 3 trials in young postmenopausal women with normal or low BMD, bone density changes versus placebo for bazedoxefine combined with conjugated oestrogens were 2.3% and 1.4% at the lumbar spine and total hip, respectively¹⁸⁷; however, no fracture data are available for the combination, only for bazedoxefine alone which significantly reduced the incidence of vertebral fracture and increased spine BMD at 3 and 7 years.¹⁸⁸ A network meta-analysis demonstrated tibolone prevented vertebral and non-vertebral fractures but not hip fractures,¹⁸⁹ with concern of cancer recurrence in women with a history of breast cancer and stroke in women over 60 years of age.¹⁹⁰

MHT has not been tested in RCTs carried out in women with established osteoporosis. Consequently, oestrogen has not been approved as a treatment for osteoporosis. A network meta-analysis found that oestrogen-progestin effectively prevented vertebral, nonvertebral, and hip fractures.¹⁸⁹ However, increased efficacy was found with bone-specific agents, such as teriparatide, abaloparatide, denosumab, and romosozumab, over hormone therapy or tibolone. Thus bone specific agents are recommended as first line treatment in postmenopausal women with established osteoporosis.

For a more in-depth discussion of osteoporosis diagnosis, prevention and treatment options, please see the International Osteoporosis Foundation (IOF) European guidance for the diagnosis and management of osteoporosis in postmenopausal women.¹⁹¹

SECTION 3: specific conditions

The presence of obesity, diabetes, history or high risk of breast cancer (BC), history of cardiovascular disease (CVD) or venous thromboembolism (VTE) is likely to make women and/or their primary care professionals unwilling to consider MHT due to anticipated risks of treatment. However, further discussion is warranted as described in the sections below.

Age

R 3.1

We suggest a targeted approach to MHT continuation in women over 60 yrs. We suggest taking into account the effect on VMS and/or other climacteric symptoms, the changing benefit-risk profile with age and effect on bone and personal preferences. (Good Clinical Practice). Age alone should not be the sole reason to discontinue MHT.^{192,193} Instead, decision making on continuation of the use of MHT beyond the age of 60 years and/or 10 years past the onset of menopause is dictated by the continued presence of bothersome menopause symptoms or for reduction of bone loss not adequately addressed by other non-hormonal options and taking into account personal preferences and quality of life. It is notable that the risk-to-benefit ratio of the use of MHT is influenced by age because age is a risk factor for cardiovascular disease and for breast cancer. However, MHT is not an anti-aging strategy and should not be used for chronic disease prevention aside from fracture risk reduction. If a decision is made to continue MHT longer-term, a non-oral route of administration should be considered at the lowest dose needed to achieve treatment goals with periodic reassessment of comorbidities and the ongoing need for MHT in collaboration with a woman's primary health care professional.

VTE

R 3.2

We recommend that, if in a woman with a previous VTE, HRT/MHT is indicated after individual risk–benefit assessment, transdermal low dose oestrogen should be used.

(⊕⊕⊕○). The route of administration of HT appears to be important when considering risk for VTE. Whereas oral HT increases risk, when administered by the transdermal route of administration it does not increase risk above baseline. Oral oestrogens undergo first-pass metabolism in the liver, which results in an increase in coagulation factors, triglycerides and C-reactive protein, adverse changes that may affect cardiovascular and thromboembolic disease risk.^{194–197} Mostly observational and some RCT data suggest that oral, but not transdermal oestrogen is associated with increased VTE risk.^{198–200} Additionally, the type of progestogen used for endometrial protection may also impact risk of VTE, with micronized progesterone and pregnane derivatives (including dydrogesterone, medrogestone, chlormadinone acetate, cyproterone acetate, and possibly medroxyprogesterone acetate) associated with no increased risk (OR 0.7; 95% CI, 0.3 to 1.9 and OR 0.9; 95% CI, 0.4 to 2.3, respectively) although not all studies give consistent results. This contrasts with norepregnane derivatives (norgestrol acetate and promegestone), which have been associated with a nearly 4-fold increased risk (OR 3.9; 95% CI 1.5 –10.0).¹⁹⁸ Similarly, a systematic review demonstrated that, in contrast to norepregnane derivatives, micronized progesterone in combination with oestrogen, was not associated with either primary or recurrent VTE risk.²⁰¹ Although RCT data are lacking, lower doses of oral HT may be associated with less risk for VTE than higher doses.²⁰² Limited data suggest that tibolone is not associated with increased risk for VTE.^{190,202,203}

Decision making regarding the use of MHT in a woman who has had a VTE is complex and takes into consideration the risk for recurrent VTE. Risk of recurrence is influenced by numerous factors including the presence of a thrombophilia, whether the VTE was provoked or unprovoked, and lifestyle factors. Expert opinion suggests that women with a history of VTE considering MHT use should be seen by a menopause expert. Existing evidence does not support testing women for the presence of a thrombophilia before starting MHT based on a family history of VTE and no or unknown thrombophilia.²⁰⁴

Cardiovascular disease

R 3.3

MHT should not be used primarily for primary or secondary prevention of cardiovascular disease (CVD). (⊕⊕⊕○). Cardiovascular disease (CVD), including coronary artery disease (CAD), represents one of the leading causes of death in the female population.²⁰⁵ Partly because of premenopausal oestrogen exposure, women are protected against CVD during their reproductive years. During perimenopause the risk for CVD increases gradually. Strong evidence shows a higher risk of CAD and CVD in women with premature or early onset menopause.⁶³ The relationship between CVD and MHT is complex and understanding has evolved over the years.

Oestrogen therapy was associated with a lower CVD risk in several observational studies.²⁰⁶ In 1991, the Nurse's Health

Study demonstrated a reduction in coronary heart disease and CVD mortality in women using oestrogen. In general, observational studies have included younger women than in the RCTs, which led to the timing hypothesis. Age-stratification analyses from the WHI trials found that MHT reduced CHD and all-cause mortality in women aged 50–59 years, but increased CHD in older women.^{155,185} This has been confirmed in other studies.^{156–158} The reduction in coronary and all-cause mortality in a low-risk population is consistent around 30%.¹⁵⁹ A nationwide database study from Finland evaluating oestradiol-based regimens in MHT users observed a reduction in mortality from CHD in MHT users, suggesting that the beneficial effects of oestrogens are not specific to the type of oestrogen prescribed.²⁰⁷

Initiating MHT in women over 60 years of age, or in women with prior CVD, should be individualized given the potentially increased CVD risk. In the Heart and Estrogen/Progestin Replacement studies (HERS and HERS II), use of CEE/MPA failed to show a reduction in the risk for nonfatal myocardial infarction (MI), CHD as well as the incidence of unstable angina, peripheral arterial disease, stroke and transient ischemic attack in the population of women with established CAD; furthermore, use of CEE/MPA was associated with increased risk for MI in the first year and CAD deaths in the first 3 years.²⁰⁸ Based on these studies, MHT prescribing rates declined.

There was no effect with MHT administration on all-cause mortality, CVD related deaths, non-fatal MI, angina, revascularization, stroke or pulmonary embolism when HRT was used for secondary prevention in a large Cochrane review. There was no strong evidence that MHT overall had an effect on death or death from cardiovascular causes; however in the subgroup analysis in this study, women who initiated MHT prior to 10 years post menopause had lower all-cause mortality and CHD benefit, compared to placebo.¹⁵⁶

Hyperlipidaemia and abnormal lipid profiles are a significant risk factor for CVD. The menopausal transition is associated with an unfavourable lipid profile and an increase in lipid parameters resulting in CAD and CVD progression. Scarce available data show that oral MHT is superior to transdermal MHT in LDL-C (low density lipoprotein) and Lp(a) reduction and HDL increase but was also associated with an increase in triglyceride concentration, therefore highlighting transdermal MHT as a safer option for women with hypertriglyceridaemia.²⁰⁹ In women with dyslipidaemia, data from small RCTs show that statin and statin + MHT is superior to MHT monotherapy in reducing triglyceride levels and therefore, the combination of transdermal MHT and statin therapy could be considered. MHT alone does not achieve recommended levels of lipids for secondary CVD prevention.^{210,211} In women with a high CVD risk and dyslipidaemia, MHT should not be introduced.²¹²

In general, MHT is contraindicated in women with existing CHD, including myocardial infarction (MI). Although it is strongly advised to stop MHT after MI, a meta-analysis showed that the absolute risk of MI, angina or death is low when continuing MHT after the event.²¹³ If MHT is indicated, discussion with a cardiologist should take place. A recent systematic review summarized the risks of MHT in women with pre-existing CVD, with varying frequency of cardiovascular risk factors.²¹¹ Most of the studies examined CEE combined with MPA and were conducted in women >60 years. Compared to placebo, MHT did not show any significant effect on non-fatal

MI (7 RCTs), CVD death (6 RCTs) or stroke (5 RCTs).²¹¹ However, these data were of low quality and insufficient to recommend the use of MHT for secondary CVD prevention.

Cardiovascular risk factors such as elevated blood pressure, lipid levels and glucose levels should always be optimized according to CVD guidelines before systemic MHT can be considered.^{140,214} Transdermal low dose MHT is preferred when cardiovascular risk factors are present.

Diabetes

R 3.4

We recommend that well-controlled diabetes is not considered a contraindication for MHT use; transdermal oestrogen is the preferred choice. (⊕⊕⊕○). There is no evidence for a negative effect of MHT on diabetes risk. Overall, the current use of MHT is linked with a lower risk for new-onset diabetes mellitus and better control of diabetes (see below).

Body composition changes become apparent from the stage of late perimenopause;^{215,216} fat mass (total and visceral) increases, lean mass decreases and energy expenditure decreases during the menopausal transition.^{216–219} Baseline adiposity and race may affect the magnitude of body composition changes.²²⁰ The changes in body composition and the ensuing increase in insulin resistance during the menopausal transition increase the risk of Type 2 diabetes mellitus (T2DM).²²¹

MHT exerts a favourable effect on body composition,^{222,223} with a decrease in visceral adipose tissue, body mass index, and android fat distribution, but there is no benefit observed for lean body mass.^{224,225} In the Kronos Early Estrogen Prevention Study (KEEPS) trial, weight and waist circumference increases were prevented by MHT, prescribed orally or transdermally during 4 years.²²⁶

A meta-analysis has shown that the use of MHT decreases insulin resistance by 13% and the incidence of T2DM by 30%²²⁷ and women on MHT have a lower risk of developing T2DM.²²⁸ The beneficial metabolic effect induced by oestrogen is likely mitigated by use of progestogens; women on oestrogen monotherapy had lower risk of incident DM compared to women treated with CEE or 17 β -oestradiol plus MPA.^{229,230} Progestogens like dydrogesterone or micronized progesterone may not adversely affect glucose metabolism.^{231,232}

Concerning women with pre-existing DM, MHT has been shown to decrease blood glucose levels by 11.5%, and HOMA-IR by 35.8%.²²⁷ There is a reduction in HbA1c and fasting blood glucose levels in women on active treatment as compared to placebo.^{233,234} A recent meta-analysis including 19 trials with a total of 1412 women showed that in women with DM at baseline, the use of MHT compared to women who were not on hormone treatment reduced HbA1c levels (average –6.08 mmol/mol, 95% CI: –8.80 to –3.36) as well as fasting glucose levels (average, –1.15 mmol/L, 95% CI: –1.78 to –0.51).²³⁵ This beneficial effect in HbA1c and fasting glucose levels was not evident in women on treatment with transdermal-only preparations when compared to controls.²³⁵ This suggests that careful thought must be given to the route of administration of the MHT.

Temporarily reduced bioavailability of oral contraception after dose escalation of tirzepatide has been reported.²³⁶ The clinical impact of this or other GLP-1 containing agents for MHT is not known.

Hypertension

R 3.5

In women with well-controlled hypertension there is no contra-indication for MHT; transdermal oestrogen is the preferred choice. (⊕⊕○○) We recommend MHT not be initiated in the presence of uncontrolled hypertension. (Good Clinical Practice). Lower levels of oestrogen in menopause may contribute to development of hypertension through several mechanisms such as systemic inflammation, alteration of the renin-angiotensin-aldosterone (RAAS) system, vascular tone, kinin-kallikrein system, sympathetic system and atrial natriuretic peptide (ANP). Furthermore, menopause is also accompanied by changes in body composition, development of metabolic syndrome, obesity and arterial stiffness adding further to the genesis of.²³⁷⁻²⁴⁰ CVD risk factors should be treated according to local protocols. Lifestyle advice, particularly regarding diet and exercise should be given.

Despite discrepancies in study designs, available evidence shows that in normotensive menopausal women, oestrogen therapy alone or combined with progestogen has a neutral on blood pressure.^{241,242} In hypertensive women, both oral and transdermal oestrogen therapy demonstrated a neutral effect in some studies, while in the WHI study, CEE (in combination with MPA or alone) increased blood pressure. Transdermal oestrogen was associated with a lower risk of hypertension development in comparison to oral oestrogen.²⁴³⁻²⁴⁸ Currently, it is not advised to commence MHT in the setting of uncontrolled hypertension.¹⁴⁰

Stroke

R 3.6

We recommend that MHT is not used to prevent stroke. (⊕○○○). Observational trials on the use of MHT and the risk of stroke have shown either a protective effect or an increased risk, whereas RCTs and meta analyses in general show an increased risk for stroke. A recent meta-analysis observed an increased risk for stroke (17 trials, 37 272 women, RR 1.17, 95% CI 1.05 to 1.29, $P = .027$).²⁴⁹ A systematic review calculated that use of MHT led to 52 more cases of stroke per 10 000 persons.²⁵⁰ Also, the stroke risk associated with MHT seems to be higher when initiated at older ages (further from start of menopause and MHT started over age 65). The first year of MHT use was associated with a significantly increased risk of any stroke (HR, 2.12 [95% CI, 1.66-2.70]), ischemic stroke (HR, 1.93 [95% CI, 1.05-3.57]), and subarachnoid haemorrhage (HR, 2.17 [95% CI, 1.25-3.78]).²⁵¹ Cochrane observed that continuous combined MHT increased the risk of stroke after 3 years' use: from 6 per 1000 to between 6 and 12 per 1000 and oestrogen only MHT increased the risk of stroke after 7 years' use from 24 per 1000 to between 25 and 40 per 1000.¹⁸⁴ Overall, the use of MHT seems to result in an increase up to 40% of ischemic stroke, but the actual event rate is low.¹⁵⁹ Low/standard dose transdermal oestradiol has a neutral effect on stroke risk, while higher doses may have an adverse effect.²⁵² There is controversial evidence of increased risk of haemorrhagic stroke with MHT administration. Although the increased risk of ischemic stroke within one year of initiation of MHT is most likely related to the procoagulant effect of oral MHT, the mechanism for increased risk of subarachnoid haemorrhage is much less clear and deserves further study.

Migraine

R 3.7

We suggest that in women with an indication for MHT and a history of migraine with aura, transdermal oestrogen is recommended. (⊕○○○). Two large cross-sectional studies^{253,254} have shown that MHT was associated with increased risk of migraine, OR 1.42 (95% CI 1.24-1.62). Transdermal oestrogen is reported to be less likely associated with migraine headaches compared with oral conjugated oestrogens.²⁵⁵ Meta-analyses have reported approximately 2-fold increased stroke²⁵⁶⁻²⁵⁸ risk associated with MHT usage in women with migraine and aura. However, migraine is most common in women aged under 50 years, so the safety of MHT in women with migraine and aura (which has a higher stroke risk compared with migraine without aura²⁵⁹) is not known. There are little available data investigating differential risks between oral and transdermal oestrogens on stroke risk in migraine with aura. However, the superior overall cardiovascular safety of transdermal MHT (R 3.2, R 3.5), makes it preferable to use transdermal administration for treating menopause in women with migraine and aura.²⁶⁰ Provocation of migraine symptoms appears dependent on levels of oestrogen exposure. For this reason, using the minimum dosage of transdermal oestradiol can be considered in women with migraine and aura.²⁶⁰

Breast cancer

R 3.8

We recommend that all women initiating MHT are informed about the increased risk for breast cancer. (Good Clinical Practice). The lifetime risk of breast cancer in the Western world is more than 10%, and 70%-80% of all breast cancers are hormone sensitive.²⁶¹ There is scientific support that combined oestrogen-progestogen treatment in women of normal menopausal age produces a duration-dependent increase in the risk of breast cancer, while the risk with oestrogen alone is less than combined HRT.^{114,115,138,139,262,263} Furthermore, the breast cancer risk is lower with sequential treatment with progestogen compared to continuous combined treatment. Other factors of importance are type of progestogen, time of initiation of treatment in relation to menopause, and patient characteristics. However, women with POI on HRT have no increased risk of breast cancer beyond the age-adjusted general population risk. Data on breast cancer risk dependent on type of treatment is described below.

Combined oestrogen-progestogen treatment. Oestrogen must always be given in combination with progestogen to women with an intact uterus (see R 2.4). In the largest RCT, the Women's Health Initiative study (WHI), continuous combined treatment with CEE and MPA increased the risk of breast cancer by an additional nine cases per 10 000 woman-years after a mean of 5.6 years of treatment compared with placebo.¹⁸⁵ A meta-analysis based on all available epidemiologic data until 2019 showed a gradual increase in breast cancer risk with a relative risk (RR) of 1.60; 95% CI 1.52-1.69 for the first four years of use which increased to RR 2.08; 95% CI 2.02-2.15 after 5-14 years of use.²⁶³ This increased risk is in line with other risk factors for breast cancer, such as obesity, high alcohol intake and low physical activity²⁶⁴ although the impact of MHT is less in obese than lean women. In the meta-

analysis, the increased risk of breast cancer persisted for at least ten years after discontinuation of treatment. Furthermore, the meta-analysis showed that the risk was higher for continuous treatment with progestogen compared to sequential treatment.²⁶³

Epidemiological data further suggest that the risk of breast cancer may be lower with MHT containing natural progesterone or dydrogesterone (structurally similar to progesterone) compared to synthetic progestogen.^{131,265,266} Tibolone is a synthetic substance with oestrogenic, progestogenic and androgenic properties that has shown varying breast cancer risk in epidemiological studies.^{203,263,267,268} However, in a Cochrane report based on four randomized studies, there was no increased risk of breast cancer with tibolone in women with no history of breast cancer (very low-quality evidence), while tibolone increases recurrent breast cancer rates in women with a history of breast cancer (moderate-quality evidence).¹⁹⁰ The impact of levonorgestrel-releasing hormone IUD on breast cancer risk is unclear. A meta-analysis based on seven observational studies showed an increased risk of breast cancer, especially for women over 50 years old (OR 1.52; 95% CI 1.34-1.72).²⁶⁹ However, data was lacking on previous use of oral contraceptives and concomitant use of MHT.

Body mass index (BMI) affects breast cancer risk in women using combined MHT so that obesity (BMI > 30) is associated with a significantly lower attributable risk compared to women who do not have obesity.²⁶³

Oestrogen only treatment. Women who have no uterus can be offered oestrogen-only treatment (see R 2.5). The increase in breast cancer risk with oestrogen alone, particularly conjugated equine oestrogen, is non-significant or considerably less compared with combined treatment.²⁷⁰ In fact, the WHI-study showed a non-significant reduced risk of invasive breast cancer after an average of 7.2 years of treatment with oestrogen alone, corresponding to seven fewer cases of breast cancer per 10 000 woman-years and HR 0.79; 95% CI 0.61-1.02.¹⁸⁵ Long-term follow-up (>20 years) of the same study showed continued reduced breast cancer incidence with oestrogen alone (HR 0.78; 95% CI, 0.65-0.93),²⁷¹ as does a recent meta-analysis.¹³⁸ On the other hand, several observational studies show a small increased risk of breast cancer,^{263,272,273} while others show a neutral effect.²⁷⁴ Thus, the precise effect of oestrogen alone therapy on the risk of breast cancer is currently still unclear.

R 3.9

We recommend that systemic MHT is not used in women with a history of breast cancer. Considerations include factors such as age and individual characteristics of the tumour. (⊕⊕○○). Combined MHT is contraindicated in women with a history of breast cancer.^{114,264} Two randomized trials have investigated breast cancer recurrence with MHT and have shown conflicting results. The HABITS study was stopped prematurely due to an increased risk of recurrence in MHT-users compared to nonusers after a median follow-up of 2.1 years (relative hazard (RH) 3.5, 95% CI 1.5-7.4),²⁷⁵ whereas the Stockholm trial showed no increased risk of recurrence with MHT use after a median follow-up of 4.1 years

(RH 0.82, 95% CI 0.35 to 1.9)²⁷⁶ and 10.8 years (HR 1.3; 95% CI 0.9-1.9).²⁷⁷ However, this study showed an increased risk of breast cancer in the contralateral breast (HR 3.6; 95% CI 1.2-10.9).²⁷⁷ MHT may be considered in exceptional circumstances with patients who have insufficient relief of climacteric symptoms from non-hormonal alternatives after consultation with their oncologist, and after careful information on benefits and risks.

Hereditary predisposition for breast cancer is not a contraindication to MHT but should be taken into account in counselling. A meta-analysis based on three cohort studies and 1100 patients showed that MHT use in women who are carriers of BRCA1 and BRCA2 mutations and who have undergone prophylactic salpingo-oophorectomy does not increase the risk of breast cancer (HR 0.98; 95% CI 0.63-1.52).²⁷⁸ In women after risk-reducing salpingo-oophorectomy in premenopause and with no previous history of breast cancer, MHT is recommended up to the age of natural menopause.²⁶⁴

POI is associated with a decreased risk of breast cancer and there is no additional risk for breast cancer with HRT^{279,280} over that for women of the same age who have normal ovarian function.

R 3.10

We suggest that low dose vaginal oestrogen, dosed to treat vaginal issues, can be considered in women with a history of breast cancer and genitourinary symptoms if other non-hormonal therapies are ineffective. (⊕○○○). Symptoms of genitourinary symptoms including dyspareunia and urinary tract problems can have a major impact on life quality and are reported by 50%-75% of women receiving adjuvant endocrine therapy and/or chemotherapy for breast cancer.²⁸¹ Treatment with aromatase inhibitors is associated with more severe symptoms than tamoxifen.²⁸¹ The recommended first line treatment is non-hormonal lubricants and moisturizers due to the risk of systemic absorption by local oestrogen.¹⁷¹ Lubricants based on water, oil, silicone or hyaluronic acid are usually used in association with sexual activity, whereas moisturizers containing polycarbophil-based polymers are used on a more regular basis.¹⁷¹ When non-hormonal therapies are ineffective, vaginal hormone therapy could be considered, such as low dose local oestradiol, estriol, the latter being a less potent oestrogen or DHEA which is converted to oestrogen and with the lowest effective dose.¹⁷¹ Studies do not support systemic absorption after 8 weeks of treatment with vaginal oestrogen.^{282,283} Cohort studies have shown no increased risk of breast cancer recurrence in women with a history of breast cancer using vaginal oestrogen for genitourinary symptoms.²⁸⁴⁻²⁸⁶ A recent systematic review and meta-analysis confirmed no increased risk of breast cancer recurrence or breast cancer mortality in these women.²⁸⁷ The decision of using vaginal oestrogen in these women should be taken in collaboration with the woman's oncologist.

Endometrial cancer

R 3.11

We suggest that initiation of MHT can be considered in women with a history of early stage endometrial cancer who are considered disease free. (⊕○○○). Women with a history

of endometrial cancer and menopausal symptoms should primarily be recommended non-hormonal treatment for symptom relief. If this treatment is insufficient, systemic MHT could be considered in women with a history of early-stage endometrial cancer who are considered disease free by their oncologist. A meta-analysis based on one randomized study and five observational studies showed no increased risk of recurrence in female survivors of endometrial cancer treated with MHT.^{288,289}

Ovarian cancer

R 3.12

We suggest that the risk for ovarian cancer is not a major determinant for the decision to initiate MHT or not. (⊕○○○). The incidence of ovarian cancer is about ten times lower than that of breast cancer.²⁹⁰ There are conflicting results regarding the risk of ovarian cancer with MHT use. A meta-analysis of epidemiological studies demonstrated a moderately increased risk of ovarian cancer by four years ongoing or recently stopped MHT use (RR 1.37; 95% CI 1.29-1.46), particularly of serous and endometrioid ovarian cancer.²⁹¹ There was no difference between combined hormone therapy and oestrogen alone. In contrast, the randomized WHI-trial showed no increased risk after 5-6 years of treatment with combined MHT (HR 1.41; 95% CI, 0.75-2.66).¹⁸⁵ However, after 20 years of follow-up, the WHI-study showed that CEE alone increased ovarian cancer incidence and ovarian cancer mortality, while CEE plus MPA did not.²⁹² Therefore, this might be taken into account when weighing ongoing benefits and potential risks in women with longer duration of MHT (see R 2.6).

R 3.13

We suggest that initiation of MHT can be considered in women with (a history of) certain subtypes of ovarian cancer. (⊕○○○). MHT appears to be safe in women experiencing menopausal symptoms and (a history of) ovarian cancer. A systematic review and meta-analysis comprising more than 1500 women with ovarian cancer showed no increased risk of cancer recurrence with MHT and instead a reduced risk of death in ovarian cancer (OR 0.47; 95% CI 0.28-0.80).^{67,293} However, caution should be considered for women with oestrogen receptor positive ovarian cancer such as serous cancer and granulosa cell tumours. It is therefore appropriate to make decisions about MHT in consultation with the woman's oncologist.

Mood and cognition

R 3.14

We recommend not to routinely use MHT to treat clinical depression in perimenopause/menopause. (⊕○○○). Cross-sectional studies have reported that the prevalence of depressive symptoms is higher during perimenopause and menopause transition compared with premenopause. For example, 45% to 68% of perimenopausal women have elevated depressive symptoms compared with 28% to 31% of premenopausal women.^{294,295} Some longitudinal studies have also observed increased risk of depressive symptoms during perimenopause.²⁹⁶⁻²⁹⁸ A recent network meta-analysis of 70

RCTs ($n=18\,530$) that oral oestrogens (SMD -0.54 ; 95% CI -0.90 to -0.10) and tibolone (SMD -0.64 95% CI -1.11 to -0.12) reduced depressive symptoms compared with placebo.²⁹⁹ The most efficacious treatment for depressive symptoms during menopause was a combination of fluoxetine plus MHT (SMD -1.59 ; 95% CI -2.64 to -0.50). However, subgroup analysis in women >1 year after menopause onset failed to show efficacy for any form of MHT (with or without fluoxetine) compared with placebo. A subgroup analysis of only perimenopausal women showed efficacy for transdermal oestrogen to improve depressive symptoms (SMD -0.95 ; 95% CI -1.77 to -0.14). A recent RCT of 172 perimenopausal and early postmenopausal reported that 12 months of transdermal oestradiol and intermittent micronized progesterone reduced risk of developing depressive symptoms compared with placebo (17.3% vs 32.3%).³⁰⁰

Cognitive symptoms such as “brain fog” are commonly reported by women during menopause.^{301,302} However, RCT data does not support the use of MHT to improve cognitive performance. The WHI Memory Study WHIMS measured mini-mental state examination (MMSE) in 7150 of women aged >65 years randomized to placebo or CEE with or without MPA for 5-7 years.³⁵ As expected, participants performed better following repeated MMSE testing; however, MMSE was significantly more likely to be 2SD below the mean in the placebo arm. A recent meta-analysis of RCTs investigating the effects of MHT on cognitive measures was conducted. This concluded that MHT was associated with reduced cognition compared with placebo (SMD -0.04 ; 95% CI -0.08 to -0.01), and that the reduction in cognitive function was only observed in women with aged >60 years.³⁰³ However, most participants in this meta-analysis were from WHIMS, questioning its power to aggregate findings with other studies.

In summary, perimenopause is a risk factor for depressive symptoms, and MHT can reduce depressive symptoms during this time. However, RCT data (dominated by WHIMS) suggest a paradoxical reduction in MMSE compared with placebo in older menopausal women. Effects of MHT on cognition in women aged <65 years (who represent the vast majority of women taking MHT) remain unclear.

Dementia

R 3.15

We recommend that MHT is not used to prevent or treat dementia. (⊕○○○). Menopause is commonly associated with increased cardiometabolic risk factors for dementia.³⁰⁴ Animal studies suggest that oestrogen has neuro-protective effects, which lead to the discussion of the potential for oestrogen supplementation to reduce dementia risk.³⁰⁵ The WHI Memory Study (WHIMS) remains the only RCT investigating the effects of MHT on dementia risk. CEE plus MPA doubled risks of all-cause dementia in women aged >65 years (40 vs 21 cases; HR 2.05. 95% CI 1.21-3.48; $P=.01$), but CEE alone was not associated with increased dementia risk (28 vs 19 cases; HR 1.49. 95% CI 0.83-2.66; $P=.18$). A “critical window” hypothesis has been proposed since some observational studies have reported reduced risks of Alzheimer's disease (AD) in the youngest women taking MHT.³⁰⁶ In 2020, two meta-analyses investigated the association of MHT with overall dementia risk and AD. Wu *et al.* suggested that AD risk was slightly increased in women taking MHT (OR 1.08, 95% CI

1.03-1.14, I2: 69%) and similar results were observed with overall dementia risk; increased AD risk only persisted for the first 5 years of taking MHT, while MHT use longer than 10 years was associated with a reduced AD risk.³⁰⁷ In contrast to Wu, a meta-analysis by Song *et al.* concluded that AD was reduced with MHT use (OR 0.67, 95% CI 0.58-0.78, $P < .001$); subgroup analysis failed to identify patient age or treatment duration as significant sources of heterogeneity of results.³⁰⁸ Divergent results of these meta-analyses illustrate the likely contributions of MHT type, participant age at MHT initiation, and study design (cross-section, cohort or RCT) on results. National, UK and Danish nested case-control studies have recently been published, but also yield differing conflicting results on dementia risk.^{309,310} Existing studies are limited by the long delay between age of menopause and onset of dementia, with studies having short term follow-up and comorbidities which may have changed. The effects of HRT on dementia risk in women with POI are not known.³¹¹

In summary, there are no consistent data to support MHT for dementia prevention, and some forms may increase dementia risk in women when it is initiated >65 years of age.

SECTION 4: future research

Menopause, a pivotal transition in a woman's life, significantly influences health. Understanding its impact is paramount. Future research will not only unveil new insights but also pave the way for improved treatments, thereby enhancing the overall health and well-being of menopausal women.

Potential areas of research identified by the working group included:

- Studying different types of progestogens, including progestin IUDs, and their long-term effects on the endometrium, breast, bone, and cardiovascular system. Although the IUD is primarily considered to have a local effect, some progestin is absorbed, and thus longer term studies are needed to understand its effects.
- Oestrogen was shown in the Women's Health initiative to reduce fractures (with and without progestin) in women not identified as having high fracture risk. However, it has not been studied for its effects on women with high fracture risk. This knowledge gap underscores the urgency of determining the effect of hormone therapy on fracture risk stratified by BMD, particularly for those already diagnosed with osteoporosis.
- Transdermal oestrogen appears safer for venous thrombosis and stroke risk than oral hormone therapy. However, the absence of head-to-head trials is a significant gap in our understanding, although it is unlikely that there will be further large RCTs in the future and it will be necessary to rely on observational studies and registry data of longer duration.
- It is crucial to conduct these trials to determine if there is any difference in breast cancer risk between transdermal versus oral oestrogen, thereby filling a critical knowledge void.
- The Women's Health Initiative followed women who were, on average, 63 years of age for approximately 5 years for those in the oestrogen/progestin arm and 7 years for oestrogen alone. However, there are limited data on long-term use of MHT greater than 5-7 years for morbidity and mortality, particularly for those women initiating

MHT before the age of 60 or within 10 years of menopause and for those using lower doses, progesterone instead of progestin, transdermal compared to oral, or oestradiol compared to CEE. Thus, additional studies with longer-term follow up are needed for morbidity and mortality in populations using doses, routes of administration, and formulations more commonly used today.

- Current data on cognition and effects of hormone therapy at preventing or accelerating Alzheimer's disease when initiated less than 10 years from menopause are limited. Also data for POI are lacking, and if there is any difference between surgical or natural menopause at an early age. Studies are needed to show if hormone therapy directly or indirectly affects cognition and risk for dementia.
- RCT data are needed to determine the effects of MHT on other age-related disorders (sarcopenia, joints, autoimmune disease).
- Longitudinal data are needed on the risks and benefits of the use of supraphysiologic dosing, such as that seen with pellets, regarding risks and benefits regarding breast, bone, cardiovascular, and cognitive effects.
- The impact of the use of testosterone for effects other than on libido needs to be studied.

Acknowledgments

The guideline authors express their gratitude to Rachel Weiss for critically reviewing the manuscript from a patient's perspective. Furthermore, the authors would like to thank and acknowledge Nick Panay, Margaret Rees and Richard Santen for their expert review. We are also grateful for all the valuable and critical comments of members of the European Society of Endocrinology. In addition, the authors would like to thank dr. J.W. Schoones for his help in conducting the literature searches.

Supplementary material

Supplementary material is available at *European Journal of Endocrinology* online.

Funding

This work is supported by the European Society of Endocrinology.

Authors' contributions

Mary Ann Lumsden (Conceptualization [lead], Methodology [equal], Supervision [equal], Validation [equal], Writing—original draft [equal], Writing—review & editing [equal]), Olaf Dekkers (Conceptualization [equal], Data curation [equal], Formal analysis [equal], Investigation [equal], Methodology [lead], Supervision [equal], Validation [equal], Writing—original draft [equal], Writing—review & editing [equal]), Stephanie Faubion (Conceptualization [equal], Data curation [equal], Investigation [equal], Validation [equal], Writing—original draft [equal], Writing—review & editing [equal]), Angelica Lindén Hirschberg (Conceptualization [equal], Data curation [equal], Investigation [equal], Validation [equal], Writing—original draft [equal], Writing—review & editing [equal]), Channa Jayasena (Conceptualization [equal], Data curation [equal], Investigation [equal], Validation [equal], Writing—original draft [equal], Writing—review & editing [equal]), Irene Lambrinoudaki (Conceptualization [equal],

Data curation [equal], Investigation [equal], Validation [equal], Writing—original draft [equal], Writing—review & editing [equal]), Yvonne Louwers (Conceptualization [equal], Data curation [equal], Investigation [equal], Validation [equal], Writing—original draft [equal], Writing—review & editing [equal]), JoAnn Pinkerton (Conceptualization [equal], Data curation [equal], Investigation [equal], Validation [equal], Writing—original draft [equal], Writing—review & editing [equal]), Antoan Stefan Sojat (Conceptualization [equal], Data curation [equal], Investigation [equal], Validation [equal], Writing—original draft [equal], Writing—review & editing [equal]), and Leonie van Hulsteijn (Conceptualization [equal], Data curation [equal], Formal analysis [equal], Investigation [equal], Methodology [supporting], Project administration [lead], Validation [equal], Visualization [equal], Writing—original draft [equal], Writing—review & editing [equal])

Conflict of interest

See [Appendix 1](#) for conflicts of interest.

References

- Ambikairajah A, Walsh E, Cherbuin N. A review of menopause nomenclature. *Reprod Health*. 2022;19(1):29. <https://doi.org/10.1186/s12978-022-01336-7>
- Soules MR, Sherman S, Parrott E, *et al*. Executive summary: stages of reproductive aging workshop (STRAW). *Climacteric*. 2001;4(4):267-272. <https://doi.org/10.1080/cmt.4.4.267.272>
- Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. *Obstet Gynecol Clin North Am*. 2011;38(3):489-501. <https://doi.org/10.1016/j.ogc.2011.05.006>
- Avis NE, Crawford SL, Greendale G, *et al*. Duration of menopausal vasomotor symptoms over the menopause transition. *JAMA Intern Med*. 2015;175(4):531-539. <https://doi.org/10.1001/jamainternmed.2014.8063>
- Lambrinoudaki I, Armeni E, Goulis D, *et al*. Menopause, well-being and health: a care pathway from the European Menopause and Andropause Society. *Maturitas*. 2022;163:1-14. <https://doi.org/10.1016/j.maturitas.2022.04.008>
- Gava G, Orsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiola MC. Cognition, mood and sleep in menopausal transition: the role of menopause hormone therapy. *Medicina (Kaunas)*. 2019;55(10):668. <https://doi.org/10.3390/medicina55100668>
- Rossouw JE, Anderson GL, Prentice RL, *et al*. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA*. 2002;288(3):321-333. <https://doi.org/10.1001/jama.288.3.321>
- Beral V; Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. *Lancet*. 2003;362(9392):419-427. [https://doi.org/10.1016/S0140-6736\(03\)14596-5](https://doi.org/10.1016/S0140-6736(03)14596-5)
- McCarty ME, Thomas HN. Differences in patient-reported hormone therapy use for menopause symptoms by provider specialty. *Climacteric*. 2021;24(6):600-604. <https://doi.org/10.1080/13697137.2021.1945026>
- Götte Eriksson R, Skalkidou A, Cruz N, Lindén Hirschberg A, Iliadis SI. Swedish physicians' knowledge of and prescribing practices for menopausal hormone therapy: a nationwide cross-sectional survey. *Maturitas*. 2025;197:108263. <https://doi.org/10.1016/j.maturitas.2025.108263>
- Dekkers OM, Burman P. ESE guidelines, why and how. *Eur J Endocrinol*. 2015;173(2):E1-E2. <https://doi.org/10.1530/EJE-15-0625>
- Bollerslev J, Rejnmark L, Marcocci C, *et al*. European Society of Endocrinology Clinical Guideline: treatment of chronic hypoparathyroidism in adults. *Eur J Endocrinol*. 2015;173(2):G1-20. <https://doi.org/10.1530/EJE-15-0628>
- Langer G, Meerpohl JJ, Perleth M, *et al*. [GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables]. *Z Evid Fortbild Qual Gesundheitswes*. 2012;106(5):357-368. <https://doi.org/10.1016/j.zefq.2012.05.017>
- Andrews JC, Schünemann HJ, Oxman AD, *et al*. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. *J Clin Epidemiol*. 2013;66(7):726-735. <https://doi.org/10.1016/j.jclinepi.2013.02.003>
- Guyatt GH, Alonso-Coello P, Schünemann HJ, *et al*. Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group. *J Clin Epidemiol*. 2016;80:3-7. <https://doi.org/10.1016/j.jclinepi.2016.07.006>
- Kingsberg SA, Derogatis L, Simon JA, *et al*. TX-004HR improves sexual function as measured by the female sexual function index in postmenopausal women with vulvar and vaginal atrophy: the REJOICE trial. *J Sex Med*. 2016;13(12):1930-1937. <https://doi.org/10.1016/j.jsxm.2016.09.002>
- Mitchell CM, Reed SD, Diem S, *et al*. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. *JAMA Intern Med*. 2018;178(5):681-690. <https://doi.org/10.1001/jamainternmed.2018.0116>
- Lillemon JN, Karstens L, Nardos R, Garg B, Boniface ER, Gregory WT. The impact of local estrogen on the urogenital microbiome in genitourinary syndrome of menopause: a randomized-controlled trial. *Female Pelvic Med Reconstr Surg*. 2022;28(6):e157-e162. <https://doi.org/10.1097/SPV.0000000000001170>
- Bride M. Low dose vaginal estrogens for the treatment of vulvovaginal atrophy: a randomized, placebo-controlled trial evaluating effect of estriol, estradiol or placebo on vulvovaginal atrophy symptoms. *J Sex Med*. 2014;11:220-221. <https://doi.org/10.1111/jsm.12552>
- Cauley JA, Robbins J, Chen Z, *et al*. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA*. 2003;290(13):1729-1738. <https://doi.org/10.1001/jama.290.13.1729>
- Cauley JA, Black DM, Barrett-Connor E, *et al*. Effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/Progestin Replacement Study (HERS). *Am J Med*. 2001;110(6):442-450. [https://doi.org/10.1016/S0002-9343\(01\)00647-7](https://doi.org/10.1016/S0002-9343(01)00647-7)
- Cherry N, Gilmour K, Hannaford P, *et al*. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. *Lancet*. 2003;360(9350):2001-2008. [https://doi.org/10.1016/S0140-6736\(02\)12001-0](https://doi.org/10.1016/S0140-6736(02)12001-0)
- Delmas PD, Confavreux E, Garnier P, *et al*. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. *Osteoporos Int*. 2000;11(2):177-187. <https://doi.org/10.1007/PL00004180>
- Komulainen MH, Kroger H, Tuppurainen MT, *et al*. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: a 5 year randomized trial. *Maturitas*. 2008;61(1-2):85-94. <https://doi.org/10.1016/j.maturitas.2008.09.012>
- Lees B, Stevenson JC. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone. *Osteoporos Int*. 2001;12(4):251-258. <https://doi.org/10.1007/s001980170113>
- Liao EY, Luo XH, Deng XA, *et al*. The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. *Endocr Res*. 2003;29(2):217-226. <https://doi.org/10.1081/ERC-120022314>
- Liu JH, Muse KN. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. *Am J Obstet Gynecol*. 2005;192(4):1316-1323; discussion 1323-4. <https://doi.org/10.1016/j.ajog.2004.12.067>
- Lufkin EG, Wahner HW, O'Fallon WM, *et al*. Treatment of postmenopausal osteoporosis with transdermal estrogen. *Ann Intern*

- Med.* 1992;117(1):1-9. <https://doi.org/10.7326/0003-4819-117-1-1>
29. Mosekilde L, Beck-Nielsen H, Sørensen OH, *et al.* Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women—results of the Danish Osteoporosis Prevention Study. *Maturitas*. 2000;36(3):181-193. [https://doi.org/10.1016/S0378-5122\(00\)00158-4](https://doi.org/10.1016/S0378-5122(00)00158-4)
30. Tierney MC, Oh P, Moineddin R, *et al.* A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. *Psychoneuroendocrinology*. 2009;34(7):1065-1074. <https://doi.org/10.1016/j.psyneuen.2009.02.009>
31. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E. Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. *Maturitas*. 2006;55(2):162-173. <https://doi.org/10.1016/j.maturitas.2006.01.012>
32. Vickers MR, MacLennan AH, Lawton B, *et al.* Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. *BMJ*. 2007;335(7613):239. <https://doi.org/10.1136/bmj.39266.425069.AD>
33. Zhu SY, Deng Y, Wang YF, Xue W, Ma X, Sun A. Bone protection for early menopausal women in China: standard or half-dose estrogen with progestin? A one-year prospective randomized trial. *Gynecol Endocrinol*. 2019;35(2):165-169. <https://doi.org/10.1080/09513590.2018.1505849>
34. Benster B, Carey A, Wadsworth F, Vashisht A, Domoney C, Studd J. A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. *Menopause Int*. 2009;15(2):63-69. <https://doi.org/10.1258/mi.2009.009014>
35. Berent-Spillon A, Briceno E, Pinsky A, *et al.* Distinct cognitive effects of estrogen and progesterone in menopausal women. *Psychoneuroendocrinology*. 2015;59:25-36. <https://doi.org/10.1016/j.psyneuen.2015.04.020>
36. Bullock JL, Massey FM, Gambrell RD Jr. Use of medroxyprogesterone acetate to prevent menopausal symptoms. *Obstet Gynecol*. 1975;46(2):165-168.
37. Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms—a placebo-controlled randomized trial in healthy postmenopausal women. *Menopause*. 2012;19(8):886-893. <https://doi.org/10.1097/gme.0b013e318247f07a>
38. Nordin BE, Jones MM, Crilly RG, Marshall DH, Brooke R. A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women. *Maturitas*. 1980;2(3):247-251. [https://doi.org/10.1016/0378-5122\(80\)90009-2](https://doi.org/10.1016/0378-5122(80)90009-2)
39. Prior JC, Cameron A, Fung M, *et al.* Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial. *Sci Rep*. 2023;13(1):9082. <https://doi.org/10.1038/s41598-023-35826-w>
40. Schiff I, Tulchinsky D, Cramer D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. *JAMA*. 1980;244(13):1443-1445. <https://doi.org/10.1001/jama.1980.03310130021021>
41. Schüssler P, Kluge M, Yassouridis A, *et al.* Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. *Psychoneuroendocrinology*. 2008;33(8):1124-1131. <https://doi.org/10.1016/j.psyneuen.2008.05.013>
42. Stephenson K, Neuenschwander PF, Kurdowska AK, Pinson B, Price C. Transdermal progesterone: effects on menopausal symptoms and on thrombotic, anticoagulant, and inflammatory factors in postmenopausal women. *Int J Pharm Compd*. 2008;12(4):295-304.
43. Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. *Menopause*. 2003;10(1):13-18. <https://doi.org/10.1097/00042192-200310010-00004>
44. Meston CM, Freihart BK, Handy AB, Kilimnik CD, Rosen RC. Scoring and interpretation of the FSFI: what can be learned from 20 years of use? *J Sex Med*. 2020;17(1):17-25. <https://doi.org/10.1016/j.jsxm.2019.10.007>
45. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. *Am J Med*. 1998;104(3):219-226. [https://doi.org/10.1016/S0002-9343\(98\)00029-1](https://doi.org/10.1016/S0002-9343(98)00029-1)
46. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. *Am J Med*. 2024;137(7):682. <https://doi.org/10.1016/j.amjmed.2024.03.007>
47. Rocca WA, Gazzuola Rocca L, Smith CY, Kapoor E, Faubion SS, Stewart EA. Frequency and type of premature or early menopause in a geographically defined American population. *Maturitas*. 2023;170:22-30. <https://doi.org/10.1016/j.maturitas.2023.01.012>
48. Li M, Zhu Y, Wei J, Chen L, Chen S, Lai D. The global prevalence of premature ovarian insufficiency: a systematic review and meta-analysis. *Climacteric*. 2023;26(2):95-102. <https://doi.org/10.1080/13697137.2022.2153033>
49. Heddar A, Ogur C, Da Costa S, *et al.* Genetic landscape of a large cohort of Primary Ovarian Insufficiency: new genes and pathways and implications for personalized medicine. *EBioMedicine*. 2022;84:104246. <https://doi.org/10.1016/j.ebiom.2022.104246>
50. Lambrinoudaki I, Paschou SA, Lumsden MA, *et al.* Premature ovarian insufficiency: a toolkit for the primary care physician. *Maturitas*. 2021;147:53-63. <https://doi.org/10.1016/j.maturitas.2020.11.004>
51. Panay N, Anderson RA, Bennie A, *et al.* Evidence-based guideline: premature ovarian insufficiency(†)(‡). *Climacteric*. 2024;27(6):510-520. <https://doi.org/10.1080/13697137.2024.2408922>
52. Panay N, Anderson RA, Bennie A, *et al.* Evidence-based guideline: premature ovarian insufficiency(). *Hum Reprod Open*. 2024;2024(4):hoae065. <https://doi.org/10.1093/hropen/hoae065>
53. Rahman R, Panay N. Diagnosis and management of premature ovarian insufficiency. *Best Pract Res Clin Endocrinol Metab*. 2021;35(6):101600. <https://doi.org/10.1016/j.beem.2021.101600>
54. Stevenson JC, Collins P, Hamoda H, *et al.* Cardiometabolic health in premature ovarian insufficiency. *Climacteric*. 2021;24(5):474-480. <https://doi.org/10.1080/13697137.2021.1910232>
55. Panay N, Anderson RA, Bennie A, *et al.* Evidence-based guideline: premature ovarian insufficiency. *Fertil Steril*. 2025;123(2):221-236. <https://doi.org/10.1016/j.fertnstert.2024.11.007>
56. Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause—global prevalence, physiology and implications. *Nat Rev Endocrinol*. 2018;14(4):199-215. <https://doi.org/10.1038/nrendo.2017.180>
57. Nelson SM, Davis SR, Kalantaridou S, Lumsden MA, Panay N, Anderson RA. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. *Hum Reprod Update*. 2023;29(3):327-346. <https://doi.org/10.1093/humupd/dmac045>
58. Anagnostis P, Siolos P, Gkekak NK, *et al.* Association between age at menopause and fracture risk: a systematic review and meta-analysis. *Endocrine*. 2019;63(2):213-224. <https://doi.org/10.1007/s12020-018-1746-6>
59. Roeters van Lennep JE, Heida KY, Bots ML, Hoek A. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. *Eur J Prev Cardiol*. 2016;23(2):178-186. <https://doi.org/10.1177/2047487314556004>
60. Karamitrou EK, Anagnostis P, Vaitis K, Athanasiadis L, Goulis DG. Early menopause and premature ovarian insufficiency are associated with increased risk of dementia: a systematic review and meta-analysis of observational studies. *Maturitas*. 2023;176:107792. <https://doi.org/10.1016/j.maturitas.2023.107792>
61. Xi D, Chen B, Tao H, Xu Y, Chen G. The risk of depressive and anxiety symptoms in women with premature ovarian

- insufficiency: a systematic review and meta-analysis. *Arch Womens Ment Health*. 2023;26(1):1-10. <https://doi.org/10.1007/s00737-022-01289-7>
62. van Zwol-Janssens C, Pastoor H, Laven JSE, Louwers YV, Jiskoot G. Sexual function in women with premature ovarian insufficiency (POI): systematic review and meta-analysis. *Maturitas*. 2024;184:107994. <https://doi.org/10.1016/j.maturitas.2024.107994>
 63. Muka T, Oliver-Williams C, Kunutsor S, *et al*. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. *JAMA Cardiol*. 2016;1(7):767-776. <https://doi.org/10.1001/jamacardio.2016.2415>
 64. Svejme O, Ahlborg HG, Nilsson JÅ, Karlsson MK. Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women. *BJOG*. 2012;119(7):810-816. <https://doi.org/10.1111/j.1471-0528.2012.03324.x>
 65. Webber L, Davies M, Anderson R, *et al*. ESHRE guideline: management of women with premature ovarian insufficiency. *Hum Reprod*. 2016;31(5):926-937. <https://doi.org/10.1093/humrep/dew027>
 66. Saadedine M, Kapoor E, Shufelt C. Functional hypothalamic amenorrhea: recognition and management of a challenging diagnosis. *Mayo Clin Proc*. 2023;98(9):1376-1385. <https://doi.org/10.1016/j.mayocp.2023.05.027>
 67. Rees M, Angioli R, Coleman RL, *et al*. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. *Maturitas*. 2020;134:56-61. <https://doi.org/10.1016/j.maturitas.2020.01.005>
 68. Davis SR, Baber R, Panay N, *et al*. Global consensus position statement on the use of testosterone therapy for women. *Climacteric*. 2019;22(5):429-434. <https://doi.org/10.1080/13697137.2019.1637079>
 69. Hamoda H, Sharma A. Premature ovarian insufficiency, early menopause, and induced menopause. *Best Pract Res Clin Endocrinol Metab*. 2024;38(1):101823. <https://doi.org/10.1016/j.beem.2023.101823>
 70. Shufelt CL, Brown V, Carpenter JS, *et al*. The 2023 nonhormone therapy position statement of the North American Menopause Society. *Menopause*. 2023;30(6):573-590. <https://doi.org/10.1097/GME.0000000000002200>
 71. Mann E, Smith MJ, Hellier J, *et al*. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. *Lancet Oncol*. 2012;13(3):309-318. [https://doi.org/10.1016/S1470-2045\(11\)70364-3](https://doi.org/10.1016/S1470-2045(11)70364-3)
 72. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flashes and night sweats (MENOS 2): a randomized controlled trial. *Menopause*. 2012;19(7):749-759. <https://doi.org/10.1097/gme.0b013e31823fe835>
 73. Keefer L, Blanchard EB. A behavioral group treatment program for menopausal hot flashes: results of a pilot study. *Appl Psychophysiol Biofeedback*. 2005;30(1):21-30. <https://doi.org/10.1007/s10484-005-2171-1>
 74. Khoshbooi R, Hassan SA, Deylami N, Muhamad R, Engku Kamarudin EM, Alareqe NA. Effects of group and individual culturally adapted cognitive behavioral therapy on depression and sexual satisfaction among perimenopausal women. *Int J Environ Res Public Health*. 2021;18(14):7711. <https://doi.org/10.3390/ijerph18147711>
 75. Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. *Menopause*. 2013;20(3):291-298. <https://doi.org/10.1097/gme.0b013e31826ce3ed>
 76. Johnson AK, Johnson AJ, Barton D, Elkins G. Hypnotic relaxation therapy and sexual function in Postmenopausal Women: results of a randomized clinical trial. *Int J Clin Exp Hypn*. 2016;64(2):213-224. <https://doi.org/10.1080/00207144.2016.1131590>
 77. Tremblay A, Sheeran L, Aranda SK. Psychoeducational interventions to alleviate hot flashes: a systematic review. *Menopause*. 2008;15(1):193-202. <https://doi.org/10.1097/gme.0b013e31805c08dc>
 78. Saensak S, Vutyavanich T, Somboonporn W, Srisurapanont M. Relaxation for perimenopausal and postmenopausal symptoms. *Cochrane Database Syst Rev*. 2014;2014(7):CD008582. <https://doi.org/10.1002/14651858.CD008582.pub2>
 79. Lindh-Åstrand L, Nedstrand E. Effects of applied relaxation on vasomotor symptoms in postmenopausal women: a randomized controlled trial. *Menopause*. 2013;20(4):401-408. <https://doi.org/10.1097/gme.0b013e318272ce80>
 80. Huang AJ, Phillips S, Schembri M, Vittinghoff E, Grady D. Device-guided slow-paced respiration for menopausal hot flashes: a randomized controlled trial. *Obstet Gynecol*. 2015;125(5):1130-1138. <https://doi.org/10.1097/AOG.0000000000000821>
 81. Sood R, Sood A, Wolf SL, *et al*. Paced breathing compared with usual breathing for hot flashes. *Menopause*. 2013;20(2):179-184. <https://doi.org/10.1097/GME.0b013e31826934b6>
 82. Carmody JF, Crawford S, Salmoirago-Blotcher E, Leung K, Churchill L, Olendzki N. Mindfulness training for coping with hot flashes: results of a randomized trial. *Menopause*. 2011;18(6):611-620. <https://doi.org/10.1097/gme.0b013e318204a05c>
 83. Lewis JE, Hilditch JR, Wong CJ. Further psychometric property development of the Menopause-Specific Quality of Life questionnaire and development of a modified version, MENQOL-Intervention questionnaire. *Maturitas*. 2005;50(3):209-221. <https://doi.org/10.1016/j.maturitas.2004.06.015>
 84. Cramer H, Lauche R, Langhorst J, Dobos G. Effectiveness of yoga for menopausal symptoms: a systematic review and meta-analysis of randomized controlled trials. *Evid Based Complement Alternat Med*. 2012;2012:863905. <https://doi.org/10.1155/2012/863905>
 85. Darsareh F, Taavoni S, Joolae S, Haghani H. Effect of aromatherapy massage on menopausal symptoms: a randomized placebo-controlled clinical trial. *Menopause*. 2012;19(9):995-999. <https://doi.org/10.1097/gme.0b013e318248ea16>
 86. Rafsanjani SML, Nejad RV, Ismailzadeh S, *et al*. Comparison of the efficacy of massage and aromatherapy massage with Geranium on depression in postmenopausal women: a clinical trial. *J Res Med Sci*. 2015;17:0-0. <https://doi.org/10.17795/zjrm970>
 87. Kazemzadeh R, Nikjou R, Rostamnegad M, Norouzi H. Effect of lavender aromatherapy on menopause hot flushing: a crossover randomized clinical trial. *J Chin Med Assoc*. 2016;79(9):489-492. <https://doi.org/10.1016/j.jcma.2016.01.020>
 88. Taavoni S, Darsareh F, Joolae S, Haghani H. The effect of aromatherapy massage on the psychological symptoms of postmenopausal Iranian women. *Complement Ther Med*. 2013;21(3):158-163. <https://doi.org/10.1016/j.ctim.2013.03.007>
 89. Liu T, Chen S, Mielke GI, McCarthy AL, Bailey TG. Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis. *Climacteric*. 2022;25(6):552-561. <https://doi.org/10.1080/13697137.2022.2097865>
 90. Choudhry DN, Saleem S, Hatim S, Irfan R. The effect of resistance training in reducing hot flashes in post-menopausal women: a meta-analysis. *J Bodyw Mov Ther*. 2024;39:335-342. <https://doi.org/10.1016/j.jbmt.2024.03.018>
 91. Leach MJ, Moore V. Black cohosh (*Cimicifuga* spp.) for menopausal symptoms. *Cochrane Database Syst Rev*. 2012;2012(9):CD007244. <https://doi.org/10.1002/14651858.CD007244.pub2>
 92. Chenoy R, Hussain S, Tayob Y, O'Brien PMS, Moss MY, Morse PF. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. *BMJ*. 1994;308(6927):501-503. <https://doi.org/10.1136/bmj.308.6927.501>
 93. Farzaneh F, Fatehi S, Sohrabi MR, Alizadeh K. The effect of oral evening primrose oil on menopausal hot flashes: a randomized clinical trial. *Arch Gynecol Obstet*. 2013;288(5):1075-1079. <https://doi.org/10.1007/s00404-013-2852-6>

94. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. *Cochrane Database Syst Rev.* 2013;2013(12):CD001395. <https://doi.org/10.1002/14651858.CD001395.pub4>
95. Johnson A, Roberts L, Elkins G. Complementary and alternative medicine for menopause. *J Evid Based Integr Med.* 2019;24:2515690X19829380. <https://doi.org/10.1177/2515690X19829380>
96. Bachmann GA, Kemmann E. Prevalence of oligomenorrhea and amenorrhea in a college population. *Am J Obstet Gynecol.* 1982;144(1):98-102. [https://doi.org/10.1016/0002-9378\(82\)90402-1](https://doi.org/10.1016/0002-9378(82)90402-1)
97. Münster K, Helm P, Schmidt L. Secondary amenorrhoea: prevalence and medical contact—a cross-sectional study from a Danish county. *Br J Obstet Gynaecol.* 1992;99(5):430-433. <https://doi.org/10.1111/j.1471-0528.1992.tb13763.x>
98. Taylor PN, Albrecht D, Scholz A, *et al.* Global epidemiology of hyperthyroidism and hypothyroidism. *Nat Rev Endocrinol.* 2018;14(5):301-316. <https://doi.org/10.1038/nrendo.2018.18>
99. Vanderpump MP, Tunbridge WMG, French JM, *et al.* The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. *Clin Endocrinol (Oxf).* 1995;43(1):55-68. <https://doi.org/10.1111/j.1365-2265.1995.tb01894.x>
100. Wiersinga WM, Poppe KG, Effraïmidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. *Lancet Diabetes Endocrinol.* 2023;11(4):282-298. [https://doi.org/10.1016/S2213-8587\(23\)00005-0](https://doi.org/10.1016/S2213-8587(23)00005-0)
101. Yatavelli RKR, Bhusal K. Prolactinoma. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2025.
102. Deswal R, Narwal V, Dang A, Pundir C. The prevalence of polycystic ovary syndrome: a brief systematic review. *J Hum Reprod Sci.* 2020;13(4):261-271. https://doi.org/10.4103/jhrs.JHRS_95_18
103. Prevalence and diagnosis of nonclassical congenital adrenal hyperplasia. *Nat Clin Pract Endocrinol Metab.* 2008;4(3):121. <https://doi.org/10.1038/ncpendmet0734>
104. Jehan S, Auguste E, Zizi F, *et al.* Obstructive sleep apnea: women's perspective. *J Sleep Med Disord.* 2016;3(6):1064.
105. Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. *Br J Dermatol.* 2018;179(2):282-289. <https://doi.org/10.1111/bjd.16481>
106. Lenders JW, Duh Q-Y, Eisenhofer G, *et al.* Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2014;99(6):1915-1942. <https://doi.org/10.1210/jc.2014-1498>
107. Aagaard C, Christophersen AS, Finnerup S, *et al.* The prevalence of acromegaly is higher than previously reported: changes over a three-decade period. *Clin Endocrinol (Oxf).* 2022;97(6):773-782. <https://doi.org/10.1111/cen.14828>
108. Caillé S, Debreuve-Theresette A, Vitellius G, Deguelte S, La Manna L, Zalzal M. Medullary thyroid cancer: epidemiology and characteristics according to data from the Marne-Ardenne register 1975–2018. *J Endocr Soc.* 2024;8(6):bvae084. <https://doi.org/10.1210/jendso/bvae084>
109. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. *Cancer.* 2001;92(8):2204-2210. [https://doi.org/10.1002/1097-0142\(20011015\)92:8<2204::AID-CNCR1564>3.0.CO;2-R](https://doi.org/10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R)
110. Galmiche M, Déchelotte P, Lambert G, Tavolacci MP. Prevalence of eating disorders over the 2000–2018 period: a systematic literature review. *Am J Clin Nutr.* 2019;109(5):1402-1413. <https://doi.org/10.1093/ajcn/nqy342>
111. Dreisler E, Kjer JJ. Asherman's syndrome: current perspectives on diagnosis and management. *Int J Womens Health.* 2019;11:191-198. <https://doi.org/10.2147/IJWH.S165474>
112. Asher GN, Corbett AH, Hawke RL. Common herbal dietary supplement-drug interactions. *Am Fam Physician.* 2017;96(2):101-107.
113. Jane FM, Davis SR. A practitioner's toolkit for managing the menopause. *Climacteric.* 2014;17(5):564-579. <https://doi.org/10.3109/13697137.2014.929651>
114. Lumsden MA. The NICE guideline—menopause: diagnosis and management. *Climacteric.* 2016;19(5):426-429. <https://doi.org/10.1080/13697137.2016.1222483>
115. Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. *Climacteric.* 2016;19(2):109-150. <https://doi.org/10.3109/13697137.2015.1129166>
116. Pinkerton JV. Hormone therapy for postmenopausal women. *N Engl J Med.* 2020;382(5):446-455. <https://doi.org/10.1056/NEJMc1714787>
117. Rees M, Abernethy K, Bachmann G, *et al.* The essential menopause curriculum for healthcare professionals: a European Menopause and Andropause Society (EMAS) position statement. *Maturitas.* 2022;158:70-77. <https://doi.org/10.1016/j.maturitas.2021.12.001>
118. Lee SR, Cho MK, Cho YJ, *et al.* The 2020 menopausal hormone therapy guidelines. *J Menopausal Med.* 2020;26(2):69-98. <https://doi.org/10.6118/jmm.20000>
119. Woods NF, Hohnssee C, Carpenter JS, *et al.* Symptom clusters among MsFLASH clinical trial participants. *Menopause.* 2016;23(2):158-165. <https://doi.org/10.1097/GME.0000000000000516>
120. Faubion SS, Enders F, Hedges MS, *et al.* Impact of menopause symptoms on women in the workplace. *Mayo Clin Proc.* 2023;98(6):833-845. <https://doi.org/10.1016/j.mayocp.2023.02.025>
121. Harlow SD, Burnett-Bowie SAM, Greendale GA, *et al.* Disparities in reproductive aging and midlife health between black and white women: the Study of Women's Health Across the Nation (SWAN). *Womens Midlife Health.* 2022;8(1):3. <https://doi.org/10.1186/s40695-022-00073-y>
122. El Khoudary SR, Aggarwal B, Beckie TM, *et al.* Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. *Circulation.* 2020;142(25):e506-e532. <https://doi.org/10.1161/CIR.0000000000000912>
123. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. *Cochrane Database Syst Rev.* 2012;2012(8):CD000402. <https://doi.org/10.1002/14651858.CD000402.pub4>
124. Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Reznicek GA. Menopausal hormone therapy and risk of endometrial cancer: a systematic review. *Cancers (Basel).* 2020;12(8):2195. <https://doi.org/10.3390/cancers12082195>
125. Fournier A, Dossus L, Mesrine S, *et al.* Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992–2008. *Am J Epidemiol.* 2014;180(5):508-517. <https://doi.org/10.1093/aje/kwu146>
126. The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. *Menopause.* 2020;27(9):976-992. <https://doi.org/10.1097/GME.0000000000001609>
127. Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. *Climacteric.* 2016;19(4):316-328. <https://doi.org/10.1080/13697137.2016.1187123>
128. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, *et al.* *The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use.* Washington (DC): National Academies Press (US); 2020.
129. The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. *JAMA.* 1996;276(17):1389-1396. <https://doi.org/10.1001/jama.1996.03540170033029>

130. Mirkin S, Goldstein SR, Archer DF, Pickar JH, Graham S, Bernick B. Endometrial safety and bleeding profile of a 17 β -estradiol/progesterone oral softgel capsule (TX-001HR). *Menopause*. 2020;27(4):410-417. <https://doi.org/10.1097/GME.0000000000001480>
131. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. *BMJ*. 2020;371:m3873. <https://doi.org/10.1136/bmj.m3873>
132. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat*. 2008;107(1):103-111. <https://doi.org/10.1007/s10549-007-9523-x>
133. Armeni E, Paschou SA, Goulis DG, Lambrinoudaki I. Hormone therapy regimens for managing the menopause and premature ovarian insufficiency. *Best Pract Res Clin Endocrinol Metab*. 2021;35(6):101561. <https://doi.org/10.1016/j.beem.2021.101561>
134. Pinkerton JV, Abraham L, Bushmakina AG, et al. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials. *J Womens Health (Larchmt)*. 2014;23(1):18-28. <https://doi.org/10.1089/jwh.2013.4392>
135. Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. *J Clin Endocrinol Metab*. 2014;99(2):E189-E198. <https://doi.org/10.1210/jc.2013-1707>
136. Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. *Obstet Gynecol*. 2013;121(5):959-968. <https://doi.org/10.1097/AOG.0b013e31828c5974>
137. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flashes. *Cochrane Database Syst Rev*. 2004;2004(4):CD002978. <https://doi.org/10.1002/14651858.CD002978.pub2>
138. Chlebowski RT, Aragaki AK, Pan K, et al. Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis. *Breast Cancer Res Treat*. 2024;206(1):177-184. <https://doi.org/10.1007/s10549-024-07307-9>
139. de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. *Maturitas*. 2016;91:153-155. <https://doi.org/10.1016/j.maturitas.2016.06.001>
140. Cho L, Kaunitz AM, Faubion SS, et al. Rethinking menopausal hormone therapy: for whom, what, when, and how long? *Circulation*. 2023;147(7):597-610. <https://doi.org/10.1161/CIRCULATIONAHA.122.061559>
141. Temkin SM, Barr E, Moore H, Caviston JP, Regensteiner JG, Clayton JA. Chronic conditions in women: the development of a National Institutes of health framework. *BMC Womens Health*. 2023;23(1):162. <https://doi.org/10.1186/s12905-023-02319-x>
142. Anagnostis P, Christou K, Artzouchaltzi AM, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis. *Eur J Endocrinol*. 2019;180(1):41-50. <https://doi.org/10.1530/EJE-18-0602>
143. Whiteley J, Wagner JS, Bushmakina A, Kopenhafer L, DiBonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. *Menopause*. 2013;20(5):518-524. <https://doi.org/10.1097/GME.0b013e31827d38a5>
144. Szmulowicz ED, Manson JAE, Rossouw JE, et al. Vasomotor symptoms and cardiovascular events in postmenopausal women. *Menopause*. 2011;18(6):603-610. <https://doi.org/10.1097/gme.0b013e3182014849>
145. El Khoudary SR, Thurston RC. Cardiovascular implications of the menopause transition: endogenous sex hormones and vasomotor symptoms. *Obstet Gynecol Clin North Am*. 2018;45(4):641-661. <https://doi.org/10.1016/j.ogc.2018.07.006>
146. Nelson HD. Menopause. *Lancet*. 2008;371(9614):760-770. [https://doi.org/10.1016/S0140-6736\(08\)60346-3](https://doi.org/10.1016/S0140-6736(08)60346-3)
147. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. *Menopause*. 2017;24(7):728-753. <https://doi.org/10.1097/GME.0000000000000921>
148. Hunter MS, Gentry-Maharaj A, Ryan A, et al. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65. *BJOG*. 2012;119(1):40-50. <https://doi.org/10.1111/j.1471-0528.2011.03166.x>
149. Hemminki E, Regushevskaya E, Luoto R, Veerus P. Variability of bothersome menopausal symptoms over time—a longitudinal analysis using the Estonian postmenopausal hormone therapy trial (EPHT). *BMC Womens Health*. 2012;12(1):44. <https://doi.org/10.1186/1472-6874-12-44>
150. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. *J Gen Intern Med*. 2008;23(9):1507-1513. <https://doi.org/10.1007/s11606-008-0655-4>
151. Thurston RC, Sutton-Tyrrell K, Everson-Rose SA, Hess R, Matthews KA. Hot flashes and subclinical cardiovascular disease: findings from the Study of Women's Health Across the Nation Heart Study. *Circulation*. 2008;118(12):1234-1240. <https://doi.org/10.1161/CIRCULATIONAHA.108.776823>
152. Thurston RC, Kuller LH, Edmundowicz D, Matthews KA. History of hot flashes and aortic calcification among postmenopausal women. *Menopause*. 2018;25(11):1291-1296. <https://doi.org/10.1097/GME.0000000000001231>
153. Crandall CJ, Aragaki A, Cauley JA, et al. Associations of menopausal vasomotor symptoms with fracture incidence. *J Clin Endocrinol Metab*. 2015;100(2):524-534. <https://doi.org/10.1210/jc.2014-3062>
154. Maki PM. Verbal memory and menopause. *Maturitas*. 2015;82(3):288-290. <https://doi.org/10.1016/j.maturitas.2015.07.023>
155. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women's health initiative randomized trials. *JAMA*. 2017;318(10):927-938. <https://doi.org/10.1001/jama.2017.11217>
156. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev*. 2015;2015(3):CD002229. <https://doi.org/10.1002/14651858.CD002229.pub4>
157. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. *Am J Med*. 2009;122(11):1016-1022.e1. <https://doi.org/10.1016/j.amjmed.2009.05.021>
158. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. *BMJ*. 2012;345:e6409. <https://doi.org/10.1136/bmj.e6409>
159. Lobo RA, Gompel A. Management of menopause: a view towards prevention. *Lancet Diabetes Endocrinol*. 2022;10(6):457-470. [https://doi.org/10.1016/S2213-8587\(21\)00269-2](https://doi.org/10.1016/S2213-8587(21)00269-2)
160. Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. *J Clin Endocrinol Metab*. 2021;106(1):1-15. <https://doi.org/10.1210/clinem.dgaa764>
161. Akhila V, Pratapkumar. A comparison of transdermal and oral HRT for menopausal symptom control. *Int J Fertil Womens Med*. 2006;51(2):64-69.
162. Ettinger B, Pressman A, Van Gessel A. Low-dosage esterified estrogens opposed by progestin at 6-month intervals. *Obstet Gynecol*. 2001;98(2):205-211. [https://doi.org/10.1016/s0029-7844\(01\)01419-3](https://doi.org/10.1016/s0029-7844(01)01419-3)

163. Lindh-Åstrand L, Brynhildsen J, Hoffman M, Hammar M. Vasomotor symptoms usually reappear after cessation of postmenopausal hormone therapy: a Swedish population-based study. *Menopause*. 2009;16(6):1213-1217. <https://doi.org/10.1097/gme.0b013e3181a53221>
164. Pinkerton JV, Sanchez Aguirre F, Blake J. The 2017 hormone therapy position statement of the North American Menopause Society. *Menopause*. 2018;25(11):1362-1387. <https://doi.org/10.1097/GME.0000000000001241>
165. Iyer TK, Fiffick AN, Batur P. Nonhormone therapies for vasomotor symptom management. *Cleve Clin J Med*. 2024;91(4):237-244. <https://doi.org/10.3949/ccjm.91a.23067>
166. Pinkerton JV, Simon J, Panay N, *et al.* Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanant for the treatment of vasomotor symptoms associated with menopause. *Menopause*. 2024;31(6):522-529. <https://doi.org/10.1097/GME.0000000000002350>
167. Chavez MP, Pasqualotto E, Ferreira ROM, *et al.* Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis. *Climacteric*. 2024;27(3):245-254. <https://doi.org/10.1080/13697137.2024.2334083>
168. Appa AA, Creasman J, Brown JS, *et al.* The impact of multimorbidity on sexual function in middle-aged and older women: beyond the single disease perspective. *J Sex Med*. 2014;11(11):2744-2755. <https://doi.org/10.1111/jsm.12665>
169. Avis NE, Brockwell S, Randolph JF, *et al.* Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. *Menopause*. 2009;16(3):442-452. <https://doi.org/10.1097/gme.0b013e3181948dd0>
170. Lonnée-Hoffmann RA, Dennerstein L, Leher P, Szoek C. Sexual function in the late postmenopause: a decade of follow-up in a population-based cohort of Australian women. *J Sex Med*. 2014;11(8):2029-2038. <https://doi.org/10.1111/jsm.12590>
171. Hirschberg AL, Bitzer J, Cano A, *et al.* Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: an EMAS clinical guide. *Maturitas*. 2021;148:55-61. <https://doi.org/10.1016/j.maturitas.2021.04.005>
172. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. *Menopause*. 2014;21(10):1063-1068. <https://doi.org/10.1097/GME.0000000000000329>
173. Nappi RE, Palacios S, Bruyniks N, Particco M, Panay N. The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. *Menopause*. 2019;26(5):485-491. <https://doi.org/10.1097/GME.0000000000001260>
174. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. *Menopause*. 2006;13(5):737-743. <https://doi.org/10.1097/01.gme.0000227401.98933.0b>
175. Wierman ME, Nappi RE, Avis N, *et al.* Endocrine aspects of women's sexual function. *J Sex Med*. 2010;7(1_Part_2):561-585. <https://doi.org/10.1111/j.1743-6109.2009.01629.x>
176. Taylor HS, Tal A, Pal L, *et al.* Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). *JAMA Intern Med*. 2017;177(10):1471-1479. <https://doi.org/10.1001/jamainternmed.2017.3877>
177. Marina L, Sojat AS, Maseroli E, Spaggiari G, Pandurevic S, Santi D. Hormonal profile of menopausal women receiving androgen replacement therapy: a meta-analysis. *J Endocrinol Invest*. 2020;43(6):717-735. <https://doi.org/10.1007/s40618-020-01192-x>
178. Jackson RD, Wactawski-Wende J, LaCroix AZ, *et al.* Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. *J Bone Miner Res*. 2006;21(6):817-828. <https://doi.org/10.1359/jbmr.060312>
179. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society* clinical practice guideline. *J Clin Endocrinol Metab*. 2019;104(5):1595-1622. <https://doi.org/10.1210/je.2019-00221>
180. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. *Menopause*. 2021;28(9):973-997. <https://doi.org/10.1097/GME.0000000000001831>
181. Wasnich RD, Bagger YZ, Hosking DJ, *et al.* Changes in bone density and turnover after alendronate or estrogen withdrawal. *Menopause*. 2004;11(6, Part 1 of 2):622-630. <https://doi.org/10.1097/01.GME.0000123641.76105.B5>
182. Anagnostis P, Divaris E, Bosdou JK, Tournis S, Stathopoulos K, Goulis DG. Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review. *Hormones (Athens)*. 2024;23(2):339-344. <https://doi.org/10.1007/s42000-024-00526-1>
183. Watts NB, Cauley JA, Jackson RD, *et al.* No increase in fractures after stopping hormone therapy: results from the women's health initiative. *J Clin Endocrinol Metab*. 2017;102(1):302-308. <https://doi.org/10.1210/je.2016-3270>
184. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev*. 2017;1(1):CD004143. <https://doi.org/10.1002/14651858.CD004143.pub5>
185. Manson JE, Chlebowski RT, Stefanick ML, *et al.* Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. *JAMA*. 2013;310(13):1353-1368. <https://doi.org/10.1001/jama.2013.278040>
186. Banks E, Beral V, Reeves G, *et al.* Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. *JAMA*. 2004;291(18):2212-2220. <https://doi.org/10.1001/jama.291.18.2212>
187. Gallagher JC, Palacios S, Ryan KA, *et al.* Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials. *Menopause*. 2016;23(10):1083-1091. <https://doi.org/10.1097/GME.0000000000000694>
188. Peng L, Luo Q, Lu H. Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2017;96(49):e8659. <https://doi.org/10.1097/MD.00000000000008659>
189. Barrionuevo P, Kapoor E, Asi N, *et al.* Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab*. 2019;104(5):1623-1630. <https://doi.org/10.1210/je.2019-00192>
190. Formoso G, Perrone E, Maltoni S, *et al.* Short-term and long-term effects of tibolone in postmenopausal women. *Cochrane Database Syst Rev*. 2016;10(10):CD008536. <https://doi.org/10.1002/14651858.CD008536.pub3>
191. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int*. 2019;30(1):3-44. <https://doi.org/10.1007/s00198-018-4704-5>
192. ACOG Practice Bulletin No. 141: management of menopausal symptoms. *Obstet Gynecol*. 2014;123(1):202-216. <https://doi.org/10.1097/01.AOG.0000441353.20693.78>
193. Gass ML, Maki PM, Shifren JL, *et al.* NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. *Menopause*. 2015;22(7):685-686. <https://doi.org/10.1097/GME.0000000000000491>
194. Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? *Thromb Haemost*. 2007;97(4):558-565. <https://doi.org/10.1160/TH06-10-0567>
195. Lacut K, Oger E, Le Gal G, *et al.* Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. *Thromb Haemost*. 2003;90(7):124-131. <https://doi.org/10.1055/s-0037-1613608>

196. Post MS, Christella M, Thomassen LGD, *et al.* Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. *Arterioscler Thromb Vasc Biol.* 2003;23(6):1116-1121. <https://doi.org/10.1161/01.ATV.0000074146.36646.C8>
197. Shifren JL, Rifai N, Desindes S, McIlwain M, Doros G, Mazer NA. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. *J Clin Endocrinol Metab.* 2008;93(5):1702-1710. <https://doi.org/10.1210/jc.2007-2193>
198. Canonico M, Oger E, Plu-Bureau G, *et al.* Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. *Circulation.* 2007;115(7):840-845. <https://doi.org/10.1161/CIRCULATIONAHA.106.642280>
199. Mohammed K, Abu Dabrh AM, Benkhadra K, *et al.* Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2015;100(11):4012-4020. <https://doi.org/10.1210/jc.2015-2237>
200. Rovinski D, Ramos RB, Figuera TM, Casanova GK, Spritzer PM. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. *Thromb Res.* 2018;168:83-95. <https://doi.org/10.1016/j.thromres.2018.06.014>
201. Kaemmler LM, Stadler A, Janka H, von Wolff M, Stute P. The impact of micronized progesterone on cardiovascular events—a systematic review. *Climacteric.* 2022;25(4):327-336. <https://doi.org/10.1080/13697137.2021.2022644>
202. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. *BMJ.* 2019;364:k4810. <https://doi.org/10.1136/bmj.k4810>
203. Cummings SR, Ettinger B, Delmas PD, *et al.* The effects of tibolone in older postmenopausal women. *N Engl J Med.* 2008;359(7):697-708. <https://doi.org/10.1056/NEJMoa0800743>
204. Middeldorp S, Nieuwlaar R, Baumann Kreuziger L, *et al.* American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. *Blood Adv.* 2023;7(22):7101-7138. <https://doi.org/10.1182/bloodadvances.2023010177>
205. Savonitto S, Colombo D, Prati F. Coronary artery disease after menopause and the role of estrogen replacement therapy. *J Cardiovasc Med (Hagerstown).* 2018;19 Suppl 1:e107-e111. <https://doi.org/10.2459/JCM.0000000000000596>
206. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. *Prev Med.* 1991;20(1):47-63. [https://doi.org/10.1016/0091-7435\(91\)90006-P](https://doi.org/10.1016/0091-7435(91)90006-P)
207. Mikkola TS, Tuomikoski P, Lyytinen H, *et al.* Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. *Menopause.* 2015;22(9):976-983. <https://doi.org/10.1097/GME.0000000000000450>
208. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. *Menopause.* 2012;19(6):616-621. <https://doi.org/10.1097/gme.0b013e31824bb039>
209. Nie G, Yang X, Wang Y, *et al.* The effects of menopause hormone therapy on lipid profile in postmenopausal women: a systematic review and meta-analysis. *Front Pharmacol.* 2022;13:850815. <https://doi.org/10.3389/fphar.2022.850815>
210. Herrington DM, Werbel BL, Riley WA, Pusser BE, Morgan TM. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. *J Am Coll Cardiol.* 1999;33(7):2030-2037. [https://doi.org/10.1016/S0735-1097\(99\)00128-X](https://doi.org/10.1016/S0735-1097(99)00128-X)
211. Bontempo S, Yeganeh L, Giri R, Vincent AJ. Use of MHT in women with cardiovascular disease: a systematic review and meta-analysis. *Climacteric.* 2024;27(1):93-103. <https://doi.org/10.1080/13697137.2023.2273524>
212. Anagnostis P, Bitzer J, Cano A, *et al.* Menopause symptom management in women with dyslipidemias: an EMAS clinical guide. *Maturitas.* 2020;135:82-88. <https://doi.org/10.1016/j.maturitas.2020.03.007>
213. Bretler DM, Hansen PR, Sorensen R, *et al.* Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study. *BMJ.* 2012;344:e1802. <https://doi.org/10.1136/bmj.e1802>
214. Maas A. Hormone therapy and cardiovascular disease: benefits and harms. *Best Pract Res Clin Endocrinol Metab.* 2021;35(6):101576. <https://doi.org/10.1016/j.beem.2021.101576>
215. Greendale GA, Han W, Finkelstein JS, *et al.* Changes in regional fat distribution and anthropometric measures across the menopause transition. *J Clin Endocrinol Metab.* 2021;106(9):2520-2534. <https://doi.org/10.1210/clinem/dgab389>
216. Greendale GA, Sternfeld B, Huang M, *et al.* Changes in body composition and weight during the menopause transition. *JCI Insight.* 2019;4(5):e124865. <https://doi.org/10.1172/jci.insight.124865>
217. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. *Int J Obes (Lond).* 2008;32(6):949-958. <https://doi.org/10.1038/ijo.2008.25>
218. Banack HR, Bea JW, Chen Z, *et al.* Longitudinal patterns of abdominal visceral and subcutaneous adipose tissue, total body composition, and anthropometric measures in postmenopausal women: results from the Women's Health Initiative. *Int J Obes (Lond).* 2023;47(4):288-296. <https://doi.org/10.1038/s41366-023-01266-9>
219. Sowers M, Zheng H, Tomey K, *et al.* Changes in body composition in women over six years at midlife: ovarian and chronological aging. *J Clin Endocrinol Metab.* 2007;92(3):895-901. <https://doi.org/10.1210/jc.2006-1393>
220. Marlatt KL, Redman LM, Beyl RA, *et al.* Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. *Am J Obstet Gynecol.* 2020;222(4):365.e1-365.e18. <https://doi.org/10.1016/j.ajog.2019.09.051>
221. Lambroudaki I, Paschou SA, Armeni E, Goulis DG. The interplay between diabetes mellitus and menopause: clinical implications. *Nat Rev Endocrinol.* 2022;18(10):608-622. <https://doi.org/10.1038/s41574-022-00708-0>
222. Papadakis GE, Hans D, Rodriguez EG, *et al.* Menopausal hormone therapy is associated with reduced total and visceral adiposity: the OsteoLaus cohort. *J Clin Endocrinol Metab.* 2018;103(5):1948-1957. <https://doi.org/10.1210/jc.2017-02449>
223. Ebong IA, Watson KE, Hairston KG, *et al.* Body fat distribution, menopausal hormone therapy and incident type 2 diabetes in postmenopausal women of the MESA study. *Maturitas.* 2016;91:147-152. <https://doi.org/10.1016/j.maturitas.2016.06.020>
224. Espeland MA, Stefanick ML, Kritz-Silverstein D, *et al.* Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. *J Clin Endocrinol Metab.* 1997;82(5):1549-1556. <https://doi.org/10.1210/jcem.82.5.3925>
225. Jensen LB, Vestergaard P, Hermann AP, *et al.* Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. *J Bone Miner Res.* 2003;18(2):333-342. <https://doi.org/10.1359/jbmr.2003.18.2.333>
226. Cintron D, Beckman JP, Bailey KR, Lahr BD, Jayachandran M, Miller VM. Plasma orexin A levels in recently menopausal women during and 3 years following use of hormone therapy. *Maturitas.* 2017;99:59-65. <https://doi.org/10.1016/j.maturitas.2017.01.016>
227. Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement

- therapy on components of the metabolic syndrome in postmenopausal women. *Diabetes Obes Metab.* 2006;8(5):538-554. <https://doi.org/10.1111/j.1463-1326.2005.00545.x>
228. Margolis KL, Bonds DE, Rodabough RJ, *et al.* Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. *Diabetologia.* 2004;47(7):1175-1187. <https://doi.org/10.1007/s00125-004-1448-x>
 229. Gartlehner G, Patel SV, Feltner C, *et al.* Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US preventive services task force. *JAMA.* 2017;318(22):2234-2249. <https://doi.org/10.1001/jama.2017.16952>
 230. Prentice RL, Aragaki AK, Chlebowski RT, *et al.* Dual-outcome intention-to-treat analyses in the Women's health initiative randomized controlled hormone therapy trials. *Am J Epidemiol.* 2020;189(9):972-981. <https://doi.org/10.1093/aje/kwaa033>
 231. Godsland IF, Manassiev NA, Felton CV, *et al.* Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women. *Clin Endocrinol (Oxf).* 2004;60(5):541-549. <https://doi.org/10.1111/j.1365-2265.2004.02017.x>
 232. Coquoz A, Gruetter C, Stute P. Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review. *Climacteric.* 2019;22(2):148-161. <https://doi.org/10.1080/13697137.2018.1514003>
 233. Andersson B, Mattsson LÅ, Hahn L, *et al.* Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. *J Clin Endocrinol Metab.* 1997;82(2):638-643. <https://doi.org/10.1210/jcem.82.2.3746>
 234. Brussaard HE, Leuven JAG, Frölich M, Kluft C, Krans HMJ. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM. *Diabetologia.* 1997;40(7):843-849. <https://doi.org/10.1007/s001250050758>
 235. Speksnijder EM, ten Noever de Brauw GV, Malekzadeh A, Bisschop PH, Stenvers DJ, Siegelar SE. Effect of postmenopausal hormone therapy on glucose regulation in women with type 1 or type 2 diabetes: a systematic review and meta-analysis. *Diabetes Care.* 2023;46(10):1866-1875. <https://doi.org/10.2337/dc23-0451>
 236. Skelley JW, Sweeney K, York AL, Glover LH. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. *J Am Pharm Assoc (2003).* 2024;64(1):204-211.e4. <https://doi.org/10.1016/j.japh.2023.10.037>
 237. Sutton-Tyrrell K, Zhao X, Santoro N, *et al.* Reproductive hormones and obesity: 9 years of observation from the Study of Women's Health Across the Nation. *Am J Epidemiol.* 2010;171(11):1203-1213. <https://doi.org/10.1093/aje/kwq049>
 238. Rossi R, Chiurlia E, Nuzzo A, Cioni E, Origliani G, Modena MG. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. *J Am Coll Cardiol.* 2004;44(8):1636-1640. <https://doi.org/10.1016/j.jacc.2004.07.027>
 239. Taddei S, Virdis A, Ghiadoni L, *et al.* Menopause is associated with endothelial dysfunction in women. *Hypertension.* 1996;28(4):576-582. <https://doi.org/10.1161/01.HYP.28.4.576>
 240. Wenger NK, Arnold A, Bairey Merz CN, *et al.* Hypertension across a woman's life cycle. *J Am Coll Cardiol.* 2018;71(16):1797-1813. <https://doi.org/10.1016/j.jacc.2018.02.033>
 241. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA.* 1996;275(5):370-375. <https://doi.org/10.1001/jama.1996.03530290040035>
 242. Steiner AZ, Hodis HN, Lobo RA, Shoupe D, Xiang M, Mack WJ. Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial. *Menopause.* 2005;12(6):728-733. <https://doi.org/10.1097/01.gme.0000184426.81190.01>
 243. Mehta J, Manson JE. Menopausal hormone therapy and hypertension: minimizing risk. *Menopause.* 2021;28(11):1201-1202. <https://doi.org/10.1097/GME.0000000000001868>
 244. Nair GV, Chaput LA, Vittinghoff E, Herrington DM. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. *Chest.* 2005;127(5):1498-1506. <https://doi.org/10.1378/chest.127.5.1498>
 245. Shimbo D, Wang L, Lamonte MJ, *et al.* The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trials. *J Hypertens.* 2014;32(10):2071-2081; discussion 2081. <https://doi.org/10.1097/HJH.0000000000000287>
 246. Issa Z, Seely EW, Rahme M, El-Hajj Fuleihan G. Effects of hormone therapy on blood pressure. *Menopause.* 2015;22(4):456-468. <https://doi.org/10.1097/GME.0000000000000322>
 247. Wild RA, Larson JC, Crandall CJ, *et al.* Hormone therapy formulation, dose, route of delivery, and risk of hypertension: findings from the Women's Health Initiative Observational Study (WHI-OS). *Menopause.* 2021;28(10):1108-1116. <https://doi.org/10.1097/GME.0000000000001828>
 248. Swica Y, Warren MP, Manson JE, *et al.* Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials. *Menopause.* 2018;25(7):753-761. <https://doi.org/10.1097/GME.0000000000001067>
 249. Zhang GQ, Chen JL, Luo Y, *et al.* Menopausal hormone therapy and women's health: an umbrella review. *PLoS Med.* 2021;18(8):e1003731. <https://doi.org/10.1371/journal.pmed.1003731>
 250. Gartlehner G, Patel SV, Reddy S, Rains C, Schwimmer M, Kahwati L. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: updated evidence report and systematic review for the US preventive services task force. *JAMA.* 2022;328(17):1747-1765. <https://doi.org/10.1001/jama.2022.18324>
 251. Johansson T, Fowler P, Ek WE, Skalkidou A, Karlsson T, Johansson Å. Oral contraceptives, hormone replacement therapy, and stroke risk. *Stroke.* 2022;53(10):3107-3115. <https://doi.org/10.1161/STROKEAHA.121.038659>
 252. Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. *BMJ.* 2010;340:c2519. <https://doi.org/10.1136/bmj.c2519>
 253. Misakian AL, Langer RD, Bensenor IM, *et al.* Postmenopausal hormone therapy and migraine headache. *J Womens Health (Larchmt).* 2003;12(10):1027-1036. <https://doi.org/10.1089/154099903322643956>
 254. Aegidius KL, Zwart J-A, Hagen K, Schei B, Stovner LJ. Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. *Eur J Neurol.* 2007;14(1):73-78. <https://doi.org/10.1111/j.1468-1331.2006.01557.x>
 255. Nappi RE, Cagnacci A, Granella F, Piccinini F, Polatti F, Facchinetti F. Course of primary headaches during hormone replacement therapy. *Maturitas.* 2001;38(2):157-163. [https://doi.org/10.1016/S0378-5122\(00\)00215-2](https://doi.org/10.1016/S0378-5122(00)00215-2)
 256. Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. *Am J Med.* 2010;123(7):612-624. <https://doi.org/10.1016/j.amjmed.2009.12.021>
 257. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. *BMJ.* 2009;339:b3914. <https://doi.org/10.1136/bmj.b3914>
 258. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. *BMJ.* 2005;330(7482):63. <https://doi.org/10.1136/bmj.38302.504063.8F>

259. Øie LR, Kurth T, Gulati S, Dodick DW. Migraine and risk of stroke. *J Neurol Neurosurg Psychiatry*. 2020;91(6):593-604. <https://doi.org/10.1136/jnnp-2018-318254>
260. MacGregor EA. Migraine, menopause and hormone replacement therapy. *Post Reprod Health*. 2018;24(1):11-18. <https://doi.org/10.1177/2053369117731172>
261. Łukasiewicz S, Czelelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. *Cancers (Basel)*. 2021;13(17):4287. <https://doi.org/10.3390/cancers13174287>
262. Chlebowski RT, Aragaki AK. The Women's Health Initiative randomized trials of menopausal hormone therapy and breast cancer: findings in context. *Menopause*. 2023;30(4):454-461. <https://doi.org/10.1097/GME.0000000000002154>
263. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. *Lancet*. 2019;394(10204):1159-1168. [https://doi.org/10.1016/S0140-6736\(19\)31709-X](https://doi.org/10.1016/S0140-6736(19)31709-X)
264. "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. *Menopause*. 2022;29(7):767-794. <https://doi.org/10.1097/GME.0000000000002028>
265. Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. *Gynecol Endocrinol*. 2017;33(2):87-92. <https://doi.org/10.1080/09513590.2016.1248932>
266. Stute P, Wildt L, Neulen J. The impact of micronized progesterone on breast cancer risk: a systematic review. *Climacteric*. 2018; 21(2):111-122. <https://doi.org/10.1080/13697137.2017.1421925>
267. Chlebowski RT, Anderson GL. Changing concepts: menopausal hormone therapy and breast cancer. *J Natl Cancer Inst*. 2012;104(7):517-527. <https://doi.org/10.1093/jnci/djs014>
268. Opatrny L, Dell'Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. *BJOG*. 2008;115(2):169-175; discussion 175. <https://doi.org/10.1111/j.1471-0528.2007.01520.x>
269. Conz L, Mota BS, Bahamondes L, et al. Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand*. 2020;99(8): 970-982. <https://doi.org/10.1111/aogs.13817>
270. Santen RJ, Heitjan DF, Gompel A, et al. Underlying breast cancer risk and menopausal hormone therapy. *J Clin Endocrinol Metab*. 2020;105(6):e2299-e2307. <https://doi.org/10.1210/clinem/dgaa073>
271. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials. *JAMA*. 2020;324(4):369-380. <https://doi.org/10.1001/jama.2020.9482>
272. Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. *Int J Cancer*. 2011;128(1):144-156. <https://doi.org/10.1002/ijc.25314>
273. Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. *Am J Epidemiol*. 2009;170(1):12-23. <https://doi.org/10.1093/aje/kwp115>
274. Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, et al. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. *Menopause*. 2016;23(11):1199-1203. <https://doi.org/10.1097/GME.0000000000000698>
275. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. *Lancet*. 2004;363(9407):453-455. [https://doi.org/10.1016/S0140-6736\(04\)15493-7](https://doi.org/10.1016/S0140-6736(04)15493-7)
276. von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. *J Natl Cancer Inst*. 2005;97(7):533-535. <https://doi.org/10.1093/jnci/dji071>
277. Fahlén M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. *Eur J Cancer*. 2013;49(1):52-59. <https://doi.org/10.1016/j.ejca.2012.07.003>
278. Marchetti C, De Felice F, Boccia S, et al. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a meta-analysis. *Crit Rev Oncol Hematol*. 2018;132:111-115. <https://doi.org/10.1016/j.critrevonc.2018.09.018>
279. Titus-Ernstoff L, Longnecker MP, Newcomb PA, et al. Menstrual factors in relation to breast cancer risk. *Cancer Epidemiol Biomarkers Prev*. 1998;7(9):783-789.
280. Ewertz M, Møller M, Poulson AH, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. *Br J Cancer*. 2005;92(7):1293-1297. <https://doi.org/10.1038/sj.bjc.6602472>
281. Crean-Tate KK, Faubion SS, Pederson HJ, Vencil JA, Batur P. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. *Am J Obstet Gynecol*. 2020;222(2):103-113. <https://doi.org/10.1016/j.ajog.2019.08.043>
282. Pavlović RT, Janković SM, Milovanović JR, et al. The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis. *Clin Breast Cancer*. 2019;19(6): e731-e740. <https://doi.org/10.1016/j.clbc.2019.07.007>
283. Hirschberg AL, Sánchez-Rovira P, Presa-Lorite J, et al. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial. *Menopause*. 2020;27(5):526-534. <https://doi.org/10.1097/GME.0000000000001497>
284. Le Ray I, Dell'Aniello S, Bonnetain F, Azoulay L, Suissa S. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. *Breast Cancer Res Treat*. 2012;135(2):603-609. <https://doi.org/10.1007/s10549-012-2198-y>
285. McVicker L, Labeit AM, Coupland CAC, et al. Vaginal estrogen therapy use and survival in females with breast cancer. *JAMA Oncol*. 2024;10(1):103-108. <https://doi.org/10.1001/jamaoncol.2023.4508>
286. Agrawal P, Singh SM, Able C, et al. Safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with a history of breast cancer. *Obstet Gynecol*. 2023;142(3):660-668. <https://doi.org/10.1097/AOG.0000000000005294>
287. Beste ME, Kaunitz AM, McKinney JA, Sanchez-Ramos L. Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks. *Am J Obstet Gynecol*. 2025;232(3):262-270.e1. <https://doi.org/10.1016/j.ajog.2024.10.054>
288. Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. *Eur J Cancer*. 2014;50(9):1628-1637. <https://doi.org/10.1016/j.ejca.2014.03.006>
289. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. *Cochrane Database Syst Rev*. 2018;5(5):CD008830. <https://doi.org/10.1002/14651858.CD008830.pub3>
290. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. *Cancer Biol Med*. 2017;14(1):9-32. <https://doi.org/10.20892/j.issn.2095-3941.2016.0084>
291. Beral V, Gaitskill K, Hermon C, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of

- 52 epidemiological studies. *Lancet*. 2015;385(9980):1835-1842. [https://doi.org/10.1016/S0140-6736\(14\)61687-1](https://doi.org/10.1016/S0140-6736(14)61687-1)
292. Chlebowski RT, Aragaki AK, Pan K, et al. Menopausal hormone therapy and ovarian and endometrial cancers: long-term follow-up of the women's health initiative randomized trials. *J Clin Oncol*. 2024;42(30):3537-3549. <https://doi.org/10.1200/JCO.23.01918>
293. Pergialiotis V, Pitsouni E, Prodromidou A, Frountzas M, Perrea DN, Vlachos GD. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. *Menopause*. 2016;23(3):335-342. <https://doi.org/10.1097/GME.0000000000000508>
294. Brown JP, Gallicchio L, Flaws JA, Tracy JK. Relations among menopausal symptoms, sleep disturbance and depressive symptoms in midlife. *Maturitas*. 2009;62(2):184-189. <https://doi.org/10.1016/j.maturitas.2008.11.019>
295. Timur S, Şahin NH. The prevalence of depression symptoms and influencing factors among perimenopausal and postmenopausal women. *Menopause*. 2010;17(3):545-551. <https://doi.org/10.1097/gme.0b013e3181cf8997>
296. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). *J Affect Disord*. 2007;103(1-3):267-272. <https://doi.org/10.1016/j.jad.2007.01.034>
297. Morrison MF, Freeman EW, Lin H, Sammel MD. Higher DHEA-S (dehydroepiandrosterone sulfate) levels are associated with depressive symptoms during the menopausal transition: results from the PENN Ovarian Aging Study. *Arch Womens Ment Health*. 2011;14(5):375-382. <https://doi.org/10.1007/s00737-011-0231-5>
298. Woods NF, Smith-DiJulio K, Percival DB, Tao EY, Mariella A, Mitchell ES. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. *Menopause*. 2008;15(2):223-232. <https://doi.org/10.1097/gme.0b013e3181450fc2>
299. Tseng PT, Chiu HJ, Suen MW, et al. Pharmacological interventions and hormonal therapies for depressive symptoms in peri- and post-menopausal women: a network meta-analysis of randomized controlled trials. *Psychiatry Res*. 2023;326:115316. <https://doi.org/10.1016/j.psychres.2023.115316>
300. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. *JAMA Psychiatry*. 2018;75(2):149-157. <https://doi.org/10.1001/jamapsychiatry.2017.3998>
301. Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a systematic review and meta-analysis. *J Steroid Biochem Mol Biol*. 2014;142:90-98. <https://doi.org/10.1016/j.jsbmb.2013.06.001>
302. Maki PM, Jaff NG. Brain fog in menopause: a health-care professional's guide for decision-making and counseling on cognition. *Climacteric*. 2022;25(6):570-578. <https://doi.org/10.1080/13697137.2022.2122792>
303. Zhou HH, Yu Z, Luo L, Xie F, Wang Y, Wan Z. The effect of hormone replacement therapy on cognitive function in healthy postmenopausal women: a meta-analysis of 23 randomized controlled trials. *Psychogeriatrics*. 2021;21(6):926-938. <https://doi.org/10.1111/psyg.12768>
304. Sochocka M, Karska J, Pszczółowska M, et al. Cognitive decline in early and premature menopause. *Int J Mol Sci*. 2023;24(7):6566. <https://doi.org/10.3390/ijms24076566>
305. Morrison JH, Brinton RD, Schmidt PJ, Gore AC. Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. *J Neurosci*. 2006;26(41):10332-10348. <https://doi.org/10.1523/JNEUROSCI.3369-06.2006>
306. Daniel JM. Estrogens, estrogen receptors, and female cognitive aging: the impact of timing. *Horm Behav*. 2013;63(2):231-237. <https://doi.org/10.1016/j.yhbeh.2012.05.003>
307. Wu M, Li M, Yuan J, et al. Postmenopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease: a systematic review and time-response meta-analysis. *Pharmacol Res*. 2020;155:104693. <https://doi.org/10.1016/j.phrs.2020.104693>
308. Song YJ, Li SR, Li XW, et al. The effect of estrogen replacement therapy on Alzheimer's disease and Parkinson's disease in postmenopausal women: a meta-analysis. *Front Neurosci*. 2020;14:157. <https://doi.org/10.3389/fnins.2020.00157>
309. Vinogradova Y, Denning T, Hippisley-Cox J, Taylor L, Moore M, Coupland C. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. *BMJ*. 2021;374:n2182. <https://doi.org/10.1136/bmj.n2182>
310. Pourhadi N, Mørch LS, Holm EA, Torp-Pedersen C, Meaidi A. Menopausal hormone therapy and dementia: nationwide, nested case-control study. *BMJ*. 2023;381:e072770. <https://doi.org/10.1136/bmj-2022-072770>
311. Rocca WA, Kantarci K, Faubion SS. Risks and benefits of hormone therapy after menopause for cognitive decline and dementia: a conceptual review. *Maturitas*. 2024;184:108003. <https://doi.org/10.1016/j.maturitas.2024.108003>